

Systematic review

Colorectal cancer and microbiota modulation for clinical use. A systematic review.

Julio Madrigal-Matute and Sara Bañón Escandell*

Biomedical Institute for Nutrition and Health (IBIONS).

**Corresponding author:*

Julio Madrigal-Matute, PhD

Biomedical Institute for Nutrition and Health (IBIONS).

Phone: +34606008917;

Madrigal-matute@ibions.com

Abstract

Colorectal cancer is one of the top contributors to the global burden of cancer incidence and mortality with genetic and environmental factors contributing to its etiology. Modifiable or environmental factors can be the cause of up to 60% of the risk of developing colorectal cancer. Hence, there is a growing interest in specifically defining what can be improved in our lifestyle to reduce this risk, improve the effectiveness of treatments, reduce side effects, and decrease the risk of recurrence. One of the elements directly related to lifestyle is gut microbiota. The microbial ecosystem has a vital role in colorectal cancer prevention and antitumoral response through modulation of the immune system and production of short-chain fatty acids. Numerous approaches have been used to identify healthy microbiota that can reduce the risk of cancer development, improve treatment efficacy, and reduce side effects.

Scientific literature in this subject is growing exponentially and, therefore, systematic reviews and meta-analysis are required to ensure that appropriate recommendations are given to patients.

This work aimed to perform a systematic analysis of the published literature to elucidate whether microbiota modulation through pre-, pro-, symbiotic treatment and/or nutritional intervention can be beneficial for patients diagnosed with colorectal cancer.

Detailed analysis of published studies shows that some prebiotics, such as inulin and resistant starch, probiotics such as lactic strains producers of short-chain fatty acids, and consumption of unprocessed plant products, can be effective recommendations for patients diagnosed with colorectal cancer. This advice should always be individually tailored and followed up by a healthcare professional with expertise in the field.

Keywords: cancer, colorectal, nutrition, diet, probiotic, prebiotic, symbiotic, immunotherapy, immune system.

Abbreviations:

CRC, colorectal cancer; ROS, reactive oxygen species; RNS, reactive nitrogen species; MSI, Microsatellite instability; SCFA, Short chain fatty acids; LPS, Lipopolysaccharide; dMMR, deficient DNA mismatch repair; AOM, Azoxymethane; DSS, Dextran sodium sulfate; TNF- α , tumor necrosis factor alpha; MPO, Myeloperoxidase; PCNA, Proliferation cellular nuclear antigen; SLC5A8, Solute Carrier Family 5 Member 8; GPR43, G protein-coupled receptor 43; CEA, Carcinoembryonic antigen; APC, Adenomatous polyposis coli; DHM, 1,2-dimethyl hydrazine; TGF- β , Transforming growth factor beta; TLR2, toll-like receptor 2; DC, dendritic cells; PD-1, Programmed cell death protein 1; PDL-1, Programmed cell death protein ligand 1; CTLA-4, Cytotoxic T-Lymphocyte Associated Protein 4; CYP, Cytochrome P450 Family; GSTM1, Glutathione S-Transferase Mu 1; SULT1, Sulfotransferase Family-1; PYY, Peptide tyrosine; PPAR γ , peroxisome proliferator activated receptor gamma; 6,6BR, 6-bromoisatin; NE, marine extract; MD, Mediterranean diet; LFD, low fat diet; HFD, high fat diet; EPA, Eicosapentanoic acid; PUFA, polyunsaturated fatty acids; CRP, C reactive protein; SFRP2, Secreted Frizzled Related Protein 2; DNMT1, DNA Methyltransferase 1; COX-2, Cyclooxygenase-2; PGE₂, Prostaglandin E2; Cxcl, C-X-C Motif Chemokine Ligand; Bik, BCL2 Interacting Killer; KC, Keratinocytes-derived chemokine; Gr-1, Glucocorticoid Receptor-1; CTNNB1, Beta catenin 1; EGFR, Epidermal growth factor receptor; TYMS, Thymidylate Synthetase; LPE, Lisophosphatidiletanolamine; LPC, Lisophosphatidylcholine; G-CSF, Granulocyte Colony-Stimulating Factor; GM-CSF, Granulocyte Macrophage Colony-Stimulating Factor; HDAC, Histone Deacetylase; JAM1, F11 Receptor; 5-FU, 5-florouracil; EGCG, epigallocatechin-3-gallate;

1

2

1. Introduction

3

1.1. Colorectal cancer

4 Colorectal cancer (CRC) is a disease based on an important genetic component,
5 coupled with key influence from our lifestyle habits. Approximately 10-20% of
6 diagnoses of CRC have a family history with the disease,¹ and through family and
7 twin studies, heritability is estimated to range from 12-35%.^{2, 3} Although numerous
8 genome-wide association studies have been performed identifying genes that
9 increase susceptibility to develop CRC,⁴ many risk factors remain unknown.
10 However, only 5-7% of patients' colon cancer has a clear genetic origin.⁵ Hereditary
11 CRC syndromes can be subdivided into those associated with polyposis and those
12 without polyposis (Lynch syndrome and familial CRC).⁶ Risk factors also include the
13 development of inflammatory bowel disease, including Chron's disease and
14 ulcerative colitis. These pathologies significantly increase the chances of developing
15 CRC, being highly dependent on environmental and nutritional factors.⁷ Specifically,
16 geographical differences in incidence of CRC are influenced by genetic, and mainly
17 environmental and nutritional risks.⁸

18 It is not surprising that environmental factors have such a strong influence on the
19 risk of developing colon cancer, as the intestinal epithelium is one of the tissues with
20 the highest turnover rate in our body and is in continuous direct contact with
21 nutrients, food toxins, and microbiota.⁹⁻¹⁴

22

Etiology

23 Among the metabolic changes that precede the development of cancer are chronic
24 cell damage due to a pathological increase in reactive oxygen and nitrogen species
25 (ROS and RNS), DNA damage, and chronic inflammation.⁶ Inflammation triggers the
26 release of pro-inflammatory cytokines into the gut to regenerate damaged tissue. In
27 certain situations, inflammation becomes chronic, forming a positive feedback loop
28 that facilitates tumor development.¹⁵ Colon tumors generally begin with the
29 transformation of stem and epithelial cells that reside at the base of the colonic
30 crypts. These cells undergo chronic damage by inflammation, oxidative stress, and/or
31 genetic mutations that evolve into a premalignant lesion or polyp.¹⁶ These polyps
32 follow two main routes of differentiation to malignancy: the *adenoma-carcinoma* type
33 (70-90%) and the *serrated* (10-20%) type. In addition, another route not associated

34 with polyposis has been described with a lower incidence, characterized by
35 *microsatellite instability* (MSI; 2-7%).¹⁷ The development of a malignant tumor is
36 estimated to take 10-15 years on average.⁶

37 **1.2. Gut microbiota**

38 The microbiome includes all types of microorganisms associated with the host,
39 interacting in a complex way and usually found in the epithelial barrier zones.¹⁸ It is
40 acquired at birth by vertical transmission and is modulated throughout our lives by
41 environmental factors.¹⁹ The microbiota is a dynamic niche that is involved in the
42 maintenance of health and in the origin and development of numerous diseases by
43 modulating the homeostasis of the immune system.²⁰ Although the mechanisms may
44 be varied, one of the most notably is the stimulation of the T-cell response, through
45 the expression of bacterial epitopes or their cross-reactivity with tumor epitopes.
46 Additionally, gut microbiota also modulates the response to tumors by inhibiting
47 specific receptors that promote inflammatory and immune responses. Finally, another
48 important mechanism carried out by the microbiota is the synthesis of metabolites,
49 such as short-chain fatty acids (SCFA), which elicit a local and systemic response in
50 the host organism.¹⁹

51 But what is the ideal microbiota composition for health? This is a question that is not
52 easy to answer, although numerous studies have attempted.^{21, 22} Analyzing a
53 metabolite panel comparing stool from healthy versus CRC patients, it was found that
54 the best marker to discern between a healthy patient and a CRC patient is primarily a
55 decrease in the CRC patient's levels of certain SCFA, in particular, acetate and
56 butyrate.²³ The protective effect of SCFA against CRC may be due to their ability to
57 decrease inflammation and modulate the immune response.²⁴ In addition, SCFA
58 inhibit proliferation and promote apoptosis in neoplastic colonocytes.²⁵

59 SCFA play a key role in maintaining intestinal health and preventing the
60 development of numerous pathologies.²⁶ They are produced by many bacteria in the
61 intestinal tract, in particular, lactic acid bacteria and bifidobacteria. SCFA transporters
62 and their receptors are the communication bridges between the microbiota and the
63 cells of the gut.²⁷ Butyrate has been shown to decrease intestinal inflammation by
64 regulating epithelial occlusive junctions,²⁸ which are essential for maintaining the
65 integrity of the intestinal barrier and mucosa by aiding in the homeostasis of ions,
66 nutrients and water.²⁹

67 Among the SCFA-producing bacteria, and specifically butyrate, are those of the
68 genus *Butyricoccus*, which could protect against colitis in patients with irritable
69 bowel syndrome, as these bacteria are reduced in affected patients.³⁰ Likewise, other
70 bacteria belonging to the phylum *Firmicutes* such as *Eubacterium rectale*,
71 *Ruminococcus albus*, *R. callidus*, *R. bromii* and *F. prausnitzii* are 5 to 10 times more
72 abundant in healthy patients than in patients with Crohn's disease.³¹ The decrease in
73 species such as *Bacteroides fragilis* and *B. vulgatus* is associated with reduced
74 levels of butyric and propionic acid and increased inflammatory markers.³²
75 Additionally, *Akkermansia muciniphila*, one of the most abundant components of the
76 intestinal microbiota, is found to be decreased in obese patients,^{33, 34} those with
77 ulcerative colitis,³⁵ and those with CRC.³⁶ *A. muciniphila* ferments mainly mucins, as
78 well as other mono- and polysaccharides, giving rise to various SCFA.³⁷
79 Taken together, it appears that SCFA-producing bacteria, such as acetate and
80 butyrate are often associated with healthier microbiota profiles. For these reasons,
81 SCFA are being tested as a therapy for CRC.³⁸

82 **Dysbiosis**

83 Pathological changes in the composition of the microbiota is known as dysbiosis.³⁹
84 This unbalance in the homeostatic microbiome is related to the origin of various types
85 of tumors due, in part, to the modulation of tumor immunity,⁴⁰ with CRC being
86 prominent among these tumor types.⁴¹ Patients with CRC are often characterized by
87 a decrease in beneficial microbiota and an increase in pathogenic opportunistic
88 microorganisms.²² This pathogenic imbalance can have a variety of origins. A
89 frequent and often underestimated cause of dysbiosis stems from intensive antibiotic
90 use.⁴²

91 Chronic intestinal inflammation and epithelial disruption, two of the most important
92 risk factors for CRC development, are related to intestinal dysbiosis.^{21, 43} Many of the
93 pathogenic species identified in different studies associated with the development of
94 CRC belong to the group of hydrogen sulfide (H₂S)-producing bacteria. These
95 bacteria can oxidize SCFA, decreasing its levels locally.⁴⁴ H₂S is highly toxic to
96 colonocytes, causes damage to the intestinal epithelium, promotes inflammation,
97 produces metabolic changes, especially through oxidation of butyrate, and can result
98 in the development of CRC.^{45, 46} H₂S is also rapidly absorbed by the mucosa,⁴⁷ which
99 can disrupt the balance between proliferation and apoptosis^{48, 49} and lead to DNA

100 damage.⁵⁰ Furthermore, feces of people at high risk of CRC recurrence have higher
101 concentrations of H₂S.⁵¹ Other studies corroborate these results by finding an
102 increase in *Fusobacterium spp.*, and more specifically *Fusobacterium nucleatum*, an
103 H₂S-producing species, in colonic tumor tissue.^{52, 53} *F. nucleatum* also promotes
104 tumor growth, cell proliferation and the acquisition of chemoresistance in CRC,
105 favoring inflammation and autophagy as a cytoprotective mechanism of the tumor.^{54,}
106 ⁵⁵

107 At the phylum level, CRC patients show increased abundance of *Proteobacteria*
108 and *Verrucomicrobia*.⁵⁶ Species associated with CRC development include
109 *Bacteroides fragilis*, *Escherichia coli*, *Peptostreptococcus spp*, *Enterococcus faecalis*,
110 *Streptococcus bovis*, or *Porphyromonas spp*.^{22, 53, 57-59} For example, *B. fragilis* and *E.*
111 *coli* play a key role in the development of familial CRC. In patients with adenomatous
112 polyposis, areas arise in the colonic mucosa where *B. fragilis* and *E. coli* accumulate,
113 leading to a local increase in oncotoxins such as *B. fragilis* toxin and colibactin. ⁶⁰
114 These oncotoxins, when transferred to the colon of mice, increase colonic tumor
115 growth and mortality.⁶⁰ In addition, *B. fragilis* levels are elevated in patients with
116 diarrhea, with chronic diarrhea being an important risk factor for the development of
117 CRC.⁶¹

118 Nonetheless, it may not be so simple to discern which bacteria are beneficial. In
119 general, it appears that it may be context-dependent and that one of the key
120 characteristics of a healthy microbiota is its beneficial/harmful microbiota ratio and/or
121 its diversity.

122 **1.3. Food and gut microbiota**

123 Due to the importance of the microbiota in health and in the origin of diseases such
124 as CRC, there is much interest in knowing how to modify the flora in order to have a
125 better homeostatic capacity. The main way in which we can interact directly with our
126 microbiota is through the food we eat.⁶² A study of monozygotic and dizygotic twins,
127 and their mothers, shows that while there is a common core microbiota, pathological
128 conditions, such as malnutrition leading to obesity, produce a significant change in
129 the microbiota. These changes result in reduced diversity and modifications in gene
130 expression and metabolic pathways.⁶² Along these lines, it has been shown that a
131 "Western" diet (high fat and sugar) can alter the microbiota in periods as short as 1-3
132 days, and that these changes can be reversed by following a healthier diet (high

133 plant).^{63, 64} These results show that a healthy diet, mainly a plant-based, can improve
134 our microbiota faster than probably any other therapeutic intervention. In fact,
135 adherence to a Mediterranean diet has been shown to have a beneficial outcome in
136 modulating the microbiota. Participants following this type of diet had higher levels of
137 SCFA, *Prevotella* and *Firmicutes* that degrade plant fibers, in addition to a higher
138 proportion of bifidobacteria/*E. coli* and better gastrointestinal habits.⁶⁵ Therefore, it is
139 likely that part of the health benefits of this dietary pattern are due to its effect on our
140 commensal flora.

141 In fact, the health benefits of certain dietary patterns, such as fiber consumption,
142 have been evaluated for decades. However, the mechanisms by which fiber
143 decreases the incidence of CRC are not fully understood. Two mechanisms that may
144 be complementary are generally postulated: i) fiber may facilitate gastrointestinal
145 transit decreasing the contact between procancerous substances and ii) the intestinal
146 epithelium, or gut bacteria may ferment fiber, producing SCFA.⁶⁶ In an attempt to
147 dissect these mechanisms, a study was conducted using a mouse model in which a
148 representative human microbiota (gnobiotic) was "seeded". It was found that a low-
149 fiber diet leads to an overgrowth of bacterial species that cause degradation of the
150 mucus lining the intestinal barrier. This makes the barrier more permeable to
151 pathogenic organisms, facilitating the development of colitis.⁶⁷ In this mouse model,
152 with a low-fiber diet, overgrowth of *B. caccae* and *A. muciniphila* was promoted, with
153 these two species being responsible for the degradation of intestinal mucus.

154 The importance of nutrition is often underestimated in most scientific and medical
155 fields; however, available data show that it is a key tool in modifying the microbiota.

156 **1.4. Probiotics**

157 Probiotics are defined as "live microorganisms that confer a health benefit when
158 administered in adequate amounts".⁶⁸ The benefits are varied and range from the
159 maintenance of intestinal homeostasis to the prevention of diarrhea, irritable bowel
160 syndrome, and constipation.⁶⁹ In addition, numerous *in vitro*,⁷⁰ preclinical⁷¹⁻⁷³ and
161 clinical studies⁷⁴ have shown that probiotics may have beneficial effects, specifically
162 in cases of CRC.

163 Probiotics exert their beneficial action by modifying the gut microbiota, improving
164 the gut barrier and its microenvironment, secreting anti-cancer metabolites, and
165 reducing inflammation.⁷⁵ In addition, probiotics have an intimate relationship with the

166 immune system, particularly through homeostasis of epithelial cell junctions and
167 modulation of T-lymphocytes and dendritic cells activation.^{36, 76} As an example,
168 *Butyricoccus pullicaecorum* reduces necrotic enteritis and pathogen abundance in
169 the caecum and ileum in broiler chickens.⁷⁷ Furthermore, its administration promotes
170 the proper functioning of the intestinal epithelial barrier and reduces colitis in
171 preclinical models.³⁰ One of the most widely used probiotics is *A. muciniphila*, which
172 has been shown in numerous studies to have a beneficial role in health maintenance
173 and a therapeutic effect on various diseases such as obesity,⁷⁸ or epithelial tumors.^{79,}
174 ⁸⁰ In this regard, it has been used in preclinical models of chronic colitis, where it
175 improved inflammatory parameters and damage in the colon.⁸¹ Additionally, lactic
176 acid bacteria have been frequently used for their health benefits and their
177 immunomodulatory effect,⁸² contributing to inhibiting the development of pathogens.⁸⁹
178 Treatment with *L. salivary* and *L. fermentum* in combination with *L. acidophilus* can
179 reduce CRC cell proliferation in experimental models.^{83, 84} Furthermore, oral
180 administration of 21 different strains of *Lachnospiraceae* attenuated colorectal
181 inflammation and improved the composition of the microbiota in preclinical models.⁸⁵

182 However, a meta-analysis evaluating the role of probiotics in cancer patients failed
183 to find a clear overall beneficial outcome, except in reducing the degree of diarrhea,
184 bowel movement, and the need for antidiarrheal drugs.⁸⁶

185 **1.5. Prebiotics**

186 Prebiotics are defined as "any substance that is selectively utilized by the recipient
187 organism and confers a health benefit".⁸⁷ One of the most studied prebiotics is inulin.
188 Inulin is part of a group of dietary fibers known as inulin-type fructans. These
189 compounds are found in numerous foods such as garlic, artichoke, onion and
190 asparagus.⁸⁸ Inulin-type fructans resist digestion in the small intestine and are
191 fermented in the colon, where they are transformed into lactic acid and SCFA,
192 improving intestinal health.^{89, 90} Inulin has been shown to increase levels of CRC-
193 protective bacteria such as *Bifidobacteria*,⁹¹ *Bacteroides*,⁹² and *Akkermansia*
194 *muciniphila*⁷⁸ in murine models.

195 The role of resistant starch as a prebiotic has also been examined in numerous
196 pathologies and its benefits have also been suggested in the field of cancer,
197 particularly in CRC.⁹³ Resistant starch is a group of carbohydrates that resist
198 digestion by pancreatic amylase in the small intestine. This type of starch then

199 reaches the colon where it is fermented by the microbiota, producing numerous
200 protective effects against tumor development, including production of SCFA
201 (butyrate), regulation of bowel movements and the reduction of colonic pH.^{93, 94} Many
202 foods contain resistant starch, such as cereals, vegetables, legumes, seeds, and
203 some nuts.^{93, 95}

204 Recent studies are using prebiotics as a basis for the synthesis of therapeutic
205 targets for cancer treatment because of their promising role in this field.⁹⁶

206 **1.6. Symbiotics**

207 Symbiotics are defined as "a mixture including live microorganisms and substrates,
208 which used selectively by the host organism confers a health benefit".⁹⁷ A distinction
209 is made between *cooperative* symbiotics, in which probiotic and prebiotic are
210 administered together and act independently contributing to the health benefit, and
211 *synergistic* symbiotics, where the probiotic uses the co-administered prebiotic as a
212 substrate.⁹⁷ The use of symbiotics is becoming increasingly common in the
213 biomedical literature as a method of enhancing the effects of pro- and prebiotics used
214 individually. For example, the combination of *Bifidobacterium animalis subsp. lactis*
215 with a resistant starch led to a decrease in the number and incidence of colon
216 neoplasms. Interestingly, the probiotic alone did not produce a similar effect. It was
217 the combination that resulted in protection against cancer development, in part
218 through increased production of SCFA.⁹⁸

219 Therefore, it seems very promising that symbiotics may play a more effective role
220 than pre- or probiotics alone.

221 **1.7. Oncological treatments and microbiota in CRC**

222 Technological advances and new therapies have dramatically increased the life
223 expectancy of CRC patients.⁶ However, CRC patients often show particularly low
224 responses to hospital treatments.⁹⁹ For this reason, numerous lines of research are
225 being devoted to better understanding the mechanisms underlying this lack of
226 response to treatments, such as immunotherapy.

227 The first evidence showing the key role that the microbiota plays in modulating the
228 body's immune response to cancer treatment came from a pioneering study showing
229 that microbial flora, and in particular lipopolysaccharide (LPS) from Gram-negative
230 bacteria, increased the activation of dendritic cells and TCD8+ lymphocytes. In this

231 way, the microbiota promoted melanoma regression after radiotherapy treatment. In
232 contrast, the use of antibiotics, inhibition of LPS and its signaling, significantly
233 diminished the effect of radiotherapy treatment.¹⁰⁰ Numerous studies have
234 corroborated these data, showing that therapies decrease their efficacy in axenic
235 (without microbial flora) or antibiotic-treated mice.^{80, 101-103} A key study in this field
236 showed that genetically identical mice from two different suppliers responded
237 unequally to the same cancer treatment, due to differences in microbiota. Not only
238 that, but cohousing or fecal transfer eliminated these differences, clearly pointing
239 towards a key role of microbiota in modulating the efficacy of cancer treatment.¹⁰⁴

240 Although the role of the microbiota has been studied in different cancer treatments
241 such as radiotherapy,¹⁰⁰ chemotherapy,¹⁰² and surgery,¹⁰⁵ most studies have focused
242 in immunotherapy.^{80, 103} This may be due to both the microbiota's promising role in
243 cancer treatment and its key role in modulating the immune response.

244 **Immunotherapy**

245 Unfortunately, a large proportion of CRC patients do not respond well to
246 immunotherapy. It is known that the effectiveness of some treatments depends, to a
247 large extent, on the individual's genetics and/or cancer phenotype⁹⁹; however, for a
248 majority of CRC patients, the cause of their lack of response is unknown.

249 Immunotherapy has promising results in numerous tumor types by inducing
250 immunity by T lymphocytes.¹⁰⁶ Thus, the anti-PD-1 drugs pembrolizumab and
251 nivolumab are effective in metastatic patients whose tumors are deficient in DNA
252 mismatch repair (dMMR) enzymes and have high microsatellite instability (MSI-H).
253 ⁹⁹For the treatment of refractory dMMR-MSI-H tumors, pembrolizumab and
254 nivolumab combined with an anti-CTLA4, ipilimumab, are used. However, in tumors
255 with active DNA repair enzymes and low microsatellite instability, which account for
256 85% all tumors, these therapies tend to be ineffective.⁹⁹ Therefore, there is great
257 interest in finding methods to improve the efficacy of these therapies in CRC.

258 Knowing the ideal composition of microbiota to improve the efficacy of
259 immunotherapy treatments is no easy task. It is likely, as mentioned above, that the
260 key lies in increasing the ratio of bacteria that are beneficial to health and decreasing
261 those that are harmful.¹⁰⁷ In this line, mice transplanted with microbiota from CRC
262 patients show, after treatment with anti-PD-1, a decrease in the anti-tumor response
263 in CRC and lower survival, compared to those transplanted with microbiota from

264 healthy controls.¹¹⁷ Among the bacteria that may be beneficial to improve
265 immunotherapy are: *Clostridiales*, *Ruminococcaceae*, *Enterococci*, *Collinsella*,
266 *Alistipes*, *Faecalibacterium spp*, *A. muciniphila*, *B. fragilis*, *Eubacterium linosum* or
267 *Bifidobacteria*, although most studies have been performed on epithelial type
268 tumors.^{19, 79, 80}

269 Therefore, the study of the microbiota in the treatment of cancer patients, especially
270 in CRC patients whose treatments do not reach the effectiveness of other types of
271 cancer, is essential.

272 **Effect of surgery on the microbiota**

273 Colorectal surgery in humans aims for total tumor removal plus the addition of a
274 safety perimeter. When this clean-border surgery is achieved, the likelihood of tumor
275 recurrence decreases considerably.¹⁰⁸ However, local recurrences are common, up
276 to 15%, the origin of which appear to be linked to the biology of the primary tumor
277 and/or seeding of the tumor bed during surgery.¹⁰⁹⁻¹¹¹ Most tumors recur at the site of
278 the anastomosis due to incomplete wound closure, the inherent porosity of the
279 junctional area, improper healing, and/or the presence of collagenolytic organisms
280 that increase porosity.^{112, 113} In this regard, a high-fat diet increases the production of
281 colorectal tumors in preclinical models of anastomosis.¹⁰⁵ This mechanism is linked
282 to the overproduction of collagenolytic organisms at the suture site. Pre-operative
283 fecal analysis shows that obese patients respond by increasing collagenolytic micro-
284 organisms after taking antibiotics. In contrast, non-obese patients have decreased
285 levels of collagenolytic micro-organisms.¹⁰⁵

286 Therefore, a healthy microbiota low in collagenolytic microorganisms is key to
287 increasing the chances of successful CRC surgery and avoiding recurrences.

288 **1.8. Study aims**

289 The overall aim of this work is to review published studies on the modification of the
290 microbiota in CRC.

291 The specific objectives of this work are to evaluate the impact of modulating the
292 microbiota in CRC patients through; 1) probiotics, 2) prebiotics, 3) symbiotics and 4)
293 nutritional changes. We aim to analyze the potential use of these approaches to
294 modulate the microbiota in CRC patients.

295

296 **2. Methods**

297 **2.1. Systematic search**

298 The search strategy was defined between January 15th and April 15th, 2021. The
299 search and filtering in the Pubmed database took place on April 24th, 2021. The
300 language used for the search and filtering of the publications was English. The
301 detailed analysis of the selected publications was carried out from April 25th to May
302 31st, 2021.

303 The search strategy included six types of terms: (1) target disease of the study; (2)
304 type of cancer; (3) microbiota and dysbiosis; (4) oncology treatment, (5) use of
305 nutrition and/or supplementation with pro-, pre- and symbiotics and (6) original
306 articles.

307 To broaden the search terms, asterisks were added to the end of the words.
308 Keywords were combined using the Boolean operators "AND", "OR" and "NOT". The
309 search strategy is detailed in Table 1.

310 The results of the different levels of the search can be found in the attached
311 supplementary files.

312 **Inclusion criteria**

313 Only original articles were selected. Biographies, commentaries, duplicate
314 publications, editorials, guides, interviews, news items, personal narratives, errata,
315 retractions, reviews, systematic reviews and meta-analyses were excluded. In the
316 next level of screening, only articles published in English that had mechanistic results
317 and outcomes, at least *in vivo*, were selected by analysis of the abstract.

318 Publications that met the criteria above were downloaded and reviewed.

319 **3. Results**

320 **3.1. Literature search**

321 Figure 1 shows the flow diagram of the search and selection process. This diagram
322 has been made by adapting the work to the guidelines for systematic searches
323 recommended by Preferred Reporting Items for Systematic Reviews and Meta-
324 Analyses (PRISMA).¹¹⁴ The Pubmed search yielded 202 results. The articles were
325 screened for eligibility criteria. As a result of the first screening, a total of 108 articles

326 were selected. After applying the next filtering on the type of results, a total of 62
327 articles remained for analysis. Of these 62 studies, 15 included human clinical trials
328 (Fig. 1).

329 **3.2. Characteristics of included results**

330 Table 2 shows the characteristics of the included studies. The type of intervention
331 performed, type of cancer, type of study, impact on the microbiota, the mechanism
332 proposed by the authors, and its impact on cancer development are shown. Finally,
333 the last column includes a more subjective criterion, namely the quality of the data
334 analyzed on a scale ranging from very low = 1, low = 2, medium = 3, high = 4, very
335 high = 5. This criterion has been assessed according to the experimental design,
336 statistical analysis and strength of the mechanisms demonstrated. Figure 2 shows
337 the distribution of the included studies.

338 **4. Discussion**

339 A patient's microbiota plays a key role in modulating the immune system as a
340 natural defense against tumor development and during cancer treatment, especially
341 in CRC.²⁰ However, there is no defined therapeutic strategy for the microbiota in a
342 CRC patient. To make the transition from clinical trials to patient treatment, it is
343 necessary to review all published data on microbiota-related therapeutic approaches
344 in CRC in a systematic way. The therapeutic modulators of the microbiome include
345 primarily probiotics, prebiotics, symbiotics and nutrition.

346 **Probiotics**

347 One of the most frequent probiotic combinations for the study of CRC is that of
348 *Lactobacillus* and *Bifidobacterium*. In several studies, pre-inoculation with
349 *Lactobacillus acidophilus* or a cocktail approved for commercial use in China, called
350 Bifico, which consists of *Bifidobacterium longum*, *Lactobacillus acidophilus*, and
351 *Enterococcus faecalis*, reduced colon tumor growth in preclinical models.^{118, 169} Bifico
352 treatment also caused a decrease in *Desulfovibrio*, *Mucispirillum* and *Odoribacter*,
353 associated with an enrichment in *Lactobacillus*.¹¹⁸ However, another study reported
354 that a combination of *Bifidobacterium* and *Lactobacillus* was not able to improve 5-
355 FU treatment, despite improving the flora composition.¹²³

356 The mixture of three different strains of *Lactobacillus* and one of *Bifidobacterium*
357 decreases the incidence and number of tumors in a preclinical model of CRC
358 associated with colitis.¹³⁰ VSL#3 is a commercial probiotic containing a mixture of
359 different strains of *Lactobacillus*, *Bifidobacterium* and *Streptococcus*. In a murine
360 model with a Western diet, treatment with VSL#3 and metformin decreases colonic
361 tumor formation, through reduced cell proliferation and macrophage infiltration.¹²⁸
362 However, VSL#3 alone shows no protection against colonic tumor development in
363 other studies.^{116, 128} In fact, in a model of colitis associated with CRC and
364 inflammation, VSL#3 increases macroscopic lesions, as well as their invasiveness
365 and histological grade.¹¹⁶ Therefore, it is important not to prescribe probiotics without
366 scientific basis.

367 In addition, the *Lactobacillus* genus alone is probably the most widely tested
368 probiotic in CRC (**Fig. 2 d&e**). A study conducted with *Lactobacillus casei* in a model
369 of CRC associated with colitis, combined with FOLFOX, showed improvement in
370 various inflammatory and microbiota parameters; however, it did not show reduction
371 in tumor development.¹²⁴ In this study, FOLFOX increases apoptosis in intestinal
372 epithelial cells, while the probiotic inhibits cell death in healthy epithelial cells.¹²⁴
373 Nonetheless, it is difficult to assess the effect of a given treatment in an animal
374 model, but it is even more complicated in models that use injections of tumor cells in
375 different (heterotopic) locations, as is the case in this study.¹²⁴ Another study with the
376 *L. casei* BL23 strain showed a total inhibition of the incidence of colorectal tumors in
377 mice. This mechanism could be associated with increased expression of Bik, a
378 proapoptotic gene, and a decrease in Ki67.¹²⁶ *Lactobacillus reuteri* strain can also
379 reduce colon tumors through the production of histamine, which is associated with a
380 decrease in inflammatory markers at both local and systemic levels.¹²⁷

381 Another well-studied probiotic is *Akkermansia muciniphila* (**Fig. 2 d**). Several
382 studies support its potential use in CRC patients with promising results. Preclinical
383 studies have shown that it is more efficient against CRC than IL-2 therapy. The
384 combination of *A. muciniphila* and IL-2 was significantly more effective than their
385 separate actions in reducing tumor volume and increasing survival.¹¹⁵ The effect of *A.*
386 *muciniphila* appears to be related to a membrane protein called Amuc, which is
387 recognized by Toll-like receptor 2 (TLR2). Cellular mechanisms and immune effects
388 mediated by TLR2 lead to increased efficacy of IL-2 immune therapy.¹¹⁵

389 Therefore, it seems that probiotics, especially lactic acid bacteria, SCFA producers
390 and *A. muciniphila* could be beneficial for patients diagnosed with CRC.

391 **Prebiotics**

392 Many of the prebiotics used in the CRC literature are oligo- and polysaccharides
393 (**Fig. 2 e & f**). Among them, pectin has shown beneficial effects such as SCFA
394 production,¹⁷⁰ reduction of ammonia,¹⁷¹ and improve glucose tolerance.¹⁷² Pectin is
395 the fundamental metabolite of plant walls, and its fermentation serves as a source of
396 energy for numerous microorganisms, producing metabolites with beneficial functions
397 for our organism.^{131, 173} Furthermore, pectin is currently used in numerous food
398 additives, so its study is of great interest.^{131, 174} In fact, it has been observed that
399 pectin can be beneficial against several types of tumors such as CRC, breast and
400 prostate cancer by halting tumor development.¹⁷⁴ Its effect seems to be mediated
401 through the increase of different SCFA-producing bacteria and in particular acetate,
402 and the enhancement of the immune response through IFN- γ -producing TCD8+. In
403 addition, a transplantation of fecal microbiota from PD-1 refractory patients showed
404 enhanced anti-tumor response in PD-1 and pectin-treated mice.¹³¹

405 Galacto-oligosaccharides derived from lactulose, and mainly lactose, have been
406 tested in preclinical models with promising results in terms of reducing tumor
407 development and modulating the microbiota.¹⁴⁰ Other well-studied oligosaccharides
408 include fructo-oligosaccharides/inulin and mucin.^{66, 132, 164} Inulin has been shown to
409 significantly reduce the volume of subcutaneously transplanted colon tumors, while
410 mucin did not cause any significant change.¹³² In another study, inulin was reported
411 to strongly inhibit tumor development through modification of the microbiota and
412 butyrate production.⁶⁶ This paper dissects the pathways leading to this effect, finding
413 that butyrate is absorbed, but not oxidized due to the Warburg effect of cancer
414 cells.¹⁷⁵ However, healthy colonocytes do use butyrate as a major source of
415 energy.¹⁷⁶ In tumor cells, butyrate accumulates in the cell interior where it inhibits
416 histone deacetylase activity, thus decreasing proliferation and increasing apoptosis.⁶⁶

417 Studies with compounds derived from citrus peel, such as polymethoxyflavones,
418 have shown positive effects in preventing the development of CRC. However,
419 mechanisms such as autophagy, which the authors highlight as possible effector
420 pathways for these compounds, are poorly analyzed and higher quality studies are
421 needed to draw valid conclusions.¹⁴² Other prebiotics, such as green tea extract

422 (EGCG), have been shown to reduce colonic tumors, but these studies are of low
423 scientific quality (grading = 1 and 2) for the reasons mentioned above. In a rat model
424 of colitis-associated cancer using EGCG and resistant starch, EGCG was shown to
425 have no effect. Only resistant starch was able to decrease colonic tumor formation
426 through a change in the microbial flora, increasing SCFA production, and decreasing
427 inflammation.¹⁵⁴

428 There is great interest among scientists in Asia, but particularly in China, in
429 demonstrating the effects of different therapeutic approaches to traditional medicine
430 through the microbiota.^{135, 148} For example, the Canmei formula contains herbs called
431 *Mume sieb* and *Marci Hieronymi*, whose more than 41 active ingredients include DL-
432 arginine, L-tyrosine, L(-)-carnitine, adenine, guanine or ambrosic acid. This
433 formulation was shown to decrease the incidence of colonic tumors by reducing
434 inflammation and improving dysbiosis.¹³⁷ Another study using a *Boswellia serrata*
435 resin extract has also demonstrated, in preclinical models, its ability to reduce colonic
436 tumor formation.¹⁴⁴ Many of these studies present positive results for the inhibition of
437 CRC development. However, in general, they are of low quality (grading = 1 and 2)
438 due to a lack of mechanistic and statistically robust data and therefore do not allow
439 for reliable conclusions to be drawn.

440 **Symbiotics**

441 One of the most interesting proposals in the literature is the possibility of using
442 symbiotics as therapeutic options to increase the efficacy of available treatments. It
443 has been observed that the use of *C. butyricum*, surrounded by dextran and bound to
444 capecitabine or diclofenac, can increase the efficacy of these chemotherapeutics by
445 >500%. This symbiotic decreases tumor invasiveness and also promotes a healthier
446 and more diverse microbiota coupled with increased production of SCFA.⁹⁶ This work
447 is interesting for clinical studies as both dextran and *C. butyricum* are approved for
448 use in food applications and showed no notable side effects.⁹⁶ Another symbiotic
449 studied is the combination of *Lactobacillus gasseri* 505 and *Cudrania tricuspidata* leaf
450 extract in fermented milk. This symbiotic was shown to reduce tumor incidence and
451 malignancy in a model of CRC-associated colitis.¹⁴⁶

452 Therefore, the use of symbiotics for improving gut microbiota in patients with CRC
453 seems promising, although more studies are needed to clearly define which
454 symbiotic should be used, the dose, the timing, and in which specific CRC patients.

455 **Healthy nutrition as a source of pre- and probiotics**

456 Most, if not all pro-, pre- and symbiotics can be obtained naturally through a healthy
457 diet. Prebiotics have been isolated from mushrooms,¹³⁸ fruits,^{142, 151} dairy,¹⁴⁰ rice,¹⁶¹
458 and green tea¹³⁸ and probiotics from fruit skins,¹¹⁷ dairy,¹²² and fermented
459 products.¹⁴⁶

460 From infancy, a balanced, non-processed plant-based nutrition is the best way to
461 have a proper gut microbiota. In fact, it has been shown that a diet high in soluble
462 fiber is not able to reverse the erosion of intestinal mucus caused by a diet without
463 fiber. However, the same diet, but high in intact plant fiber decreased mucus
464 degradation, strengthening the intestinal barrier.⁶⁷

465 Anthocyanins, compounds with a positive impact on the health of patients with
466 CRC, are present in many foods such as tea, coffee, cocoa and red fruits.¹⁷⁷ In this
467 regard, it has been shown that anthocyanins in blackberries can reduce the incidence
468 of CRC, through diminished local inflammation and improved microbiota.¹⁵¹

469 Another food with interesting results is the marine extract of certain shellfish that
470 may have anticarcinogenic effects. Using metabolomic analysis techniques, one can
471 discern which compounds are toxic to tumor cells, opening the door to precision
472 nutrition.^{147, 178} Algae-derived products such as fucoxanthin, a carotenoid present in
473 high levels in wakame (*Undaria pinnatifida*), have also shown to decrease the
474 number of adenocarcinomas and total tumors. This effect was also associated with
475 an increase in the number of *Lachnospiraceae*.¹³⁴ Spices have similarly attracted a
476 great deal of interest for their health-promoting properties. For example, nutmeg can
477 decrease the development of APC genetically engineered tumors by modulating the
478 metabolism of the microbial flora and improving lipid metabolism.¹⁵⁰ Numerous food
479 extracts are also used in traditional Chinese medicine, including American ginseng.
480 The use of this compound in a murine model prevented tumors and ameliorated
481 dysbiosis induced by different murine models of CRC and high-fat diet.^{153, 155}

482 Moving from specific foods to dietary patterns, the Mediterranean diet has been
483 shown to have beneficial effects on multiple levels, specifically in the prevention of
484 certain types of cancer.¹⁷⁹ In the case of CRC, epidemiological studies show that
485 adherence to a Mediterranean diet reduces the incidence of CRC by up to 11%.¹⁸⁰
486 Likewise, the effect of mixing a Mediterranean diet with other types of diet (low-fat or
487 high-fat Western-type diet) has been studied in models of cancer associated with

488 colitis. This study showed that consumption of the Mediterranean diet, regardless of
489 the diet with which it was mixed, decreased tumor incidence, and improved the
490 microbiota, especially when accompanying a high-fat diet.¹⁴⁹

491 **Randomized clinical trials**

492 At the highest level of scientific evidence are randomized clinical trials. Within this
493 group, those conducted with lactic acid strains stand out. Among them, a study
494 conducted with 78 patients analyzed the role of probiotics in reducing side effects
495 after CRC surgery. Inclusion criteria were a diagnosis of stage III adenomatous CRC
496 and that the patients were to undergo surgery. The probiotic group received post-
497 operative treatment with a mixture of different strains of *Lactobacillus*,
498 *Bifidobacterium*, and *Streptococcus thermophilus* for almost one year. The most
499 important conclusion of this study was that probiotic treatment decreased the most
500 frequent side effects of surgery, specifically paralytic ileus. However, limitations of
501 this study include the low number of subjects included, the apparent lack of double-
502 blinding, active placebo, and a weak statistical analysis.⁷⁴ In another clinical trial, a
503 probiotic consisting of *Bifidobacterium longum*, *Lactobacillus acidophilus* and
504 *Enterococcus faecalis* was tested in CRC patients undergoing surgery. It was shown
505 that, in addition to improving the diversity of the microbial flora, the probiotic mixture
506 was able to decrease the levels of *Fusobacterium*, a bacterium associated with the
507 development of CRC, by >500%.¹⁵⁶ In addition, its use decreased post-operative
508 infections.¹⁵⁷ Another similar probiotic mixture consisting of *Lactobacillus plantarum*,
509 *Lactobacillus acidophilus* and *Bifidobacterium longum* reduced the risk of
510 postoperative infection and improved the intestinal epithelial barrier, resulting in a
511 lower incidence of diarrhea, abdominal pain, and fever.¹⁵⁹ A study using a mixture of
512 *Bifidobacterium longum* (BB536) and *Lactobacillus johnsonii* (La1) showed that only
513 the latter (La1) colonized the gut, reducing the number of pathogenic microorganisms
514 and reducing colonic inflammation in CRC patients undergoing surgery. This result
515 shows that adding more probiotics will not have a greater effect and it is important to
516 study each strain individually and its combination before it can be recommended to
517 patients.¹⁶⁰

518 In another clinical trial, a probiotic mixture consisting of *Enterococcus*, *Clostridium*
519 and *Bacillus* was used in patients undergoing CRC surgery to discern whether their
520 consumption could ameliorate the adverse effects of surgery. It was found that peri-

521 surgical use of this mixture significantly reduced incisional infections and decreased
522 the acute inflammatory response to surgery.¹⁵⁸ However, in this study, no
523 randomization was performed, and patients were included in one group (control) or
524 the other (probiotic) according to the date of surgery, with the control group (2009-
525 2011) prior to the probiotic group (2011-2013). This does not allow for a clear
526 conclusion on the effect of the probiotic, because multiple factors may have changed
527 during those two years, including greater experience of the surgical team or better
528 technical means. In this regard, the authors describe that a higher number of
529 laparotomies were performed in the probiotic group, and that performing or not
530 performing laparotomy is a key factor related to the outcome of the surgery.¹⁵⁸

531 As far as prebiotics are concerned, rice bran is of great interest due to its large
532 commercial use. Numerous studies show the benefit of whole grain consumption in
533 the prevention of CRC.¹⁸¹ In the case of rice bran, various phytochemicals in its
534 composition have been associated with a decrease in the risk of cancer
535 development, in particular CRC.¹⁸² Its consumption increases levels of *Firmicutes*
536 and *Lactobacillus*¹⁶¹ and produces numerous metabolic modifications that could be
537 related to a decrease in the risk of developing CRC.¹⁶⁶

538 In another clinical trial with prebiotics in CRC patients, a mixture of different non-
539 digestible oligosaccharides was used for 7 days before patients underwent radical
540 surgery to remove the tumor. Both groups received the same nutrition (provided by
541 the hospital) in the 7 days before and after surgery (parenteral nutrition). Surgery
542 decreased the diversity of the microbiota in both groups, underlining the impact of
543 these interventions on gut health. Interestingly, a principal component analysis of
544 microbiome diversity was able to unequivocally identify samples from postoperative
545 patients who had received prebiotics. Furthermore, the use of these prebiotics
546 improved systemic immune function, confirming the positive effect that microbiota
547 can have on immune response. An important limitation of this study is that the
548 randomization did not specify the stage or type of tumor.¹⁶²

549 Symbiotics have also been tested in randomized clinical trials. A commercially
550 named symbiotic, simbioflora®, containing fructooligosaccharides, 3 strains of
551 *Lactobacillus*, and *Bifidobacterium lactis* showed promising results in CRC patients
552 undergoing surgery. The use of this symbiotic significantly reduced inflammation and
553 postoperative infections.¹⁶³ However, this is a small study of patients with cancer at
554 different stages, so the data should be analyzed with caution. In another study, a

555 mixture of *Bifidobacterium*, *Lactobacillus* and inulin strains was used in stage I-III
556 patients undergoing surgery. This treatment resulted in an improvement in the
557 composition of the microbial community, especially the SCFA-producing bacterium.
558 However, this study does not define blind randomization of patients and there is no
559 placebo, so the data should be also analyzed with caution.¹⁶⁴ Finally, a randomized
560 clinical study was conducted in 20 healthy subjects with backcrossed arms with the
561 aim of preventing CRC. This study of 4 weeks duration per intervention (switching
562 every 4 weeks to another arm until each group completed all 4) was done with 4
563 different arms: placebo, *Bifidobacterium lactis*, resistant starch and their combination
564 (*Bifidobacterium lactis* and resistant starch). It was shown that in healthy subjects the
565 combination of *Bifidobacterium lactis* and resistant starch increased the levels of
566 *Lachnospiraceae spp.* However, the other parameters analyzed, such as stool mass,
567 pH or ammonium, SCFA, circulating cytokines, and markers of colonic epithelial
568 health, did not change.¹⁶⁵

569 The use of pomegranate extract in patients undergoing surgical tumor resection has
570 also been investigated. Pomegranate extract was shown to produce significant
571 changes in the expression of numerous genes and microRNAs related to tumor
572 development. These results underline the crucial role of diet in modifying gene
573 expression and, therefore, in the etiology of disease.^{167, 168}

574 5. Conclusion

575 We can summarize the conclusions of this work regarding the modification of the
576 microbiota in the CRC patient as follows:

577 1) **Antibiotic use** is one of the **major deleterious factors** for the prognosis of
578 **treatment efficacy**, due to its **harmful effect on the microbiota**.

579 2) **Prebiotics** such as inulin and resistant starch can support the development of a
580 healthy microbiota.

581 3) **Probiotics**, mainly based on **SCFA-producing lactic acid strains**, show a
582 **favorable profile** in preclinical and clinical studies. However, not all strains are
583 equally favorable and are therefore not recommended for use in patients without
584 individualized study of the patient and the probiotic.

585 4) A **healthy** and varied **nutrition**, consisting mainly of unprocessed **plant-based**
586 **foods**, seems to be one of the **best sources** to maintain a **homeostatic microbiota**.

587 Finally, after a detailed analysis of the literature, in a **healthy person**, there is no
588 need to recommend the use of pre-, pro- or symbiotics in addition to a **healthy diet**.
589 However, CRC patients often have severe dysbiosis due to their own disease, and
590 broad-spectrum antibiotic use. In these patients, apart from a **healthy diet**, or if a
591 healthy diet cannot be established, carefully chosen pre-, pro- and/or symbiotics may
592 be beneficial to restore a beneficial microbiota and support the efficacy of hospital
593 treatments more effectively.

594

595 **Acknowledgements**

596 We thank Dr. Alberto Canfran-Duque and Noemi Rotllan for their for critical reading
597 of the manuscript. We apologize to those whose work could not be cited owing to
598 space limitations.

599

600 **Authors Contributions**

601 JMM designed and performed the systematic search, wrote and edited the
602 manuscript. SBE contributed to the editing and interpretation of the manuscript. All
603 authors read and edited the final draft of the manuscript.

604

605 **Competing Financial Interest**

606 The authors declare no conflicts of interest

607

608 Correspondence and requests for materials should be addressed to: madrigal-
609 matute@ibions.com.

610

611 **Data availability**

612 There are not restrictions on data availability in this manuscript.

613

614

615

616

617 **6. Bibliography**

- 618 1. Henrikson, N.B. *et al.* Family history and the natural history of colorectal
619 cancer: systematic review. *Genet Med* **17**, 702-712 (2015).
- 620 2. Czene, K., Lichtenstein, P. & Hemminki, K. Environmental and heritable
621 causes of cancer among 9.6 million individuals in the Swedish Family-Cancer
622 Database. *Int J Cancer* **99**, 260-266 (2002).
- 623 3. Lichtenstein, P. *et al.* Environmental and heritable factors in the causation of
624 cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J*
625 *Med* **343**, 78-85 (2000).
- 626 4. Jiao, S. *et al.* Estimating the heritability of colorectal cancer. *Hum Mol Genet*
627 **23**, 3898-3905 (2014).
- 628 5. Syngal, S. *et al.* ACG clinical guideline: Genetic testing and management of
629 hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol* **110**, 223-262; quiz
630 263 (2015).
- 631 6. Dekker, E., Tanis, P.J., Vleugels, J.L.A., Kasi, P.M. & Wallace, M.B. Colorectal
632 cancer. *Lancet* **394**, 1467-1480 (2019).
- 633 7. Nishida, A. *et al.* Gut microbiota in the pathogenesis of inflammatory bowel
634 disease. *Clin J Gastroenterol* **11**, 1-10 (2018).
- 635 8. Murphy, N. *et al.* Lifestyle and dietary environmental factors in colorectal
636 cancer susceptibility. *Mol Aspects Med* **69**, 2-9 (2019).
- 637 9. Crosnier, C., Stamataki, D. & Lewis, J. Organizing cell renewal in the intestine:
638 stem cells, signals and combinatorial control. *Nat Rev Genet* **7**, 349-359 (2006).
- 639 10. (IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.
640 Lyon (FR): International Agency for Research on Cancer; 2010. (IARC Monographs
641 on the Evaluation of Carcinogenic Risks to Humans, No. 92.); 2010).
- 642 11. Mottram, D.S., Wedzicha, B.L. & Dodson, A.T. Acrylamide is formed in the
643 Maillard reaction. *Nature* **419**, 448-449 (2002).
- 644 12. (IARC Working Group on the Evaluation of Carcinogenic Risks to Humans.
645 Chemical Agents and Related Occupations. Lyon (FR): International Agency for
646 Research on Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic
647 Risks to Humans, No. 100F.) 2012).

- 648 13. Diggs, D.L. *et al.* Polycyclic aromatic hydrocarbons and digestive tract
649 cancers: a perspective. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev* **29**,
650 324-357 (2011).
- 651 14. Tabatabaei, S.M., Heyworth, J.S., Knuiiman, M.W. & Fritschi, L. Dietary
652 benzo[a]pyrene intake from meat and the risk of colorectal cancer. *Cancer Epidemiol*
653 *Biomarkers Prev* **19**, 3182-3184 (2010).
- 654 15. Coussens, L.M. & Werb, Z. Inflammation and cancer. *Nature* **420**, 860-867
655 (2002).
- 656 16. Medema, J.P. Cancer stem cells: the challenges ahead. *Nat Cell Biol* **15**, 338-
657 344 (2013).
- 658 17. Cancer Genome Atlas, N. Comprehensive molecular characterization of
659 human colon and rectal cancer. *Nature* **487**, 330-337 (2012).
- 660 18. Stappenbeck, T.S. & Virgin, H.W. Accounting for reciprocal host-microbiome
661 interactions in experimental science. *Nature* **534**, 191-199 (2016).
- 662 19. Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G. & Gajewski, T.F. The microbiome
663 in cancer immunotherapy: Diagnostic tools and therapeutic strategies. *Science* **359**,
664 1366-1370 (2018).
- 665 20. Thursby, E. & Juge, N. Introduction to the human gut microbiota. *Biochem J*
666 **474**, 1823-1836 (2017).
- 667 21. Claesson, M.J. *et al.* Gut microbiota composition correlates with diet and
668 health in the elderly. *Nature* **488**, 178-184 (2012).
- 669 22. Wang, T. *et al.* Structural segregation of gut microbiota between colorectal
670 cancer patients and healthy volunteers. *ISME J* **6**, 320-329 (2012).
- 671 23. Lin, Y. *et al.* NMR-based fecal metabolomics fingerprinting as predictors of
672 earlier diagnosis in patients with colorectal cancer. *Oncotarget* **7**, 29454-29464
673 (2016).
- 674 24. Chen, J. & Vitetta, L. Inflammation-Modulating Effect of Butyrate in the
675 Prevention of Colon Cancer by Dietary Fiber. *Clin Colorectal Cancer* **17**, e541-e544
676 (2018).
- 677 25. Zeng, H., Safratowich, B.D., Wang, T.T.Y., Hamlin, S.K. & Johnson, L.K.
678 Butyrate Inhibits Deoxycholic-Acid-Resistant Colonic Cell Proliferation via Cell Cycle
679 Arrest and Apoptosis: A Potential Pathway Linking Dietary Fiber to Cancer
680 Prevention. *Mol Nutr Food Res* **64**, e1901014 (2020).

- 681 26. Tan, J. *et al.* The role of short-chain fatty acids in health and disease. *Adv*
682 *Immunol* **121**, 91-119 (2014).
- 683 27. Ganapathy, V., Thangaraju, M., Prasad, P.D., Martin, P.M. & Singh, N.
684 Transporters and receptors for short-chain fatty acids as the molecular link between
685 colonic bacteria and the host. *Curr Opin Pharmacol* **13**, 869-874 (2013).
- 686 28. Zhao, Y. *et al.* GPR43 mediates microbiota metabolite SCFA regulation of
687 antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR
688 and STAT3. *Mucosal Immunol* **11**, 752-762 (2018).
- 689 29. Madara, J.L. & Pappenheimer, J.R. Structural basis for physiological
690 regulation of paracellular pathways in intestinal epithelia. *J Membr Biol* **100**, 149-164
691 (1987).
- 692 30. Eeckhaut, V. *et al.* Butyricococcus pullicaecorum in inflammatory bowel
693 disease. *Gut* **62**, 1745-1752 (2013).
- 694 31. Kang, S. *et al.* Dysbiosis of fecal microbiota in Crohn's disease patients as
695 revealed by a custom phylogenetic microarray. *Inflamm Bowel Dis* **16**, 2034-2042
696 (2010).
- 697 32. Takaishi, H. *et al.* Imbalance in intestinal microflora constitution could be
698 involved in the pathogenesis of inflammatory bowel disease. *Int J Med Microbiol* **298**,
699 463-472 (2008).
- 700 33. Karlsson, C.L. *et al.* The microbiota of the gut in preschool children with
701 normal and excessive body weight. *Obesity (Silver Spring)* **20**, 2257-2261 (2012).
- 702 34. Crovesy, L., Masterson, D. & Rosado, E.L. Profile of the gut microbiota of
703 adults with obesity: a systematic review. *Eur J Clin Nutr* **74**, 1251-1262 (2020).
- 704 35. Vigsnaes, L.K., Brynskov, J., Steenholdt, C., Wilcks, A. & Licht, T.R. Gram-
705 negative bacteria account for main differences between faecal microbiota from
706 patients with ulcerative colitis and healthy controls. *Benef Microbes* **3**, 287-297
707 (2012).
- 708 36. Wang, L. *et al.* A purified membrane protein from Akkermansia muciniphila or
709 the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of
710 CD8(+) T cells in mice. *Gut* **69**, 1988-1997 (2020).
- 711 37. Ottman, N. *et al.* Genome-Scale Model and Omics Analysis of Metabolic
712 Capacities of Akkermansia muciniphila Reveal a Preferential Mucin-Degrading
713 Lifestyle. *Appl Environ Microbiol* **83** (2017).

- 714 38. Wang, G. *et al.* Role of SCFAs in gut microbiome and glycolysis for colorectal
715 cancer therapy. *J Cell Physiol* **234**, 17023-17049 (2019).
- 716 39. Petersen, C. & Round, J.L. Defining dysbiosis and its influence on host
717 immunity and disease. *Cell Microbiol* **16**, 1024-1033 (2014).
- 718 40. Wong, S.H. & Yu, J. Gut microbiota in colorectal cancer: mechanisms of action
719 and clinical applications. *Nat Rev Gastroenterol Hepatol* **16**, 690-704 (2019).
- 720 41. Peters, B.A. *et al.* The gut microbiota in conventional and serrated precursors
721 of colorectal cancer. *Microbiome* **4**, 69 (2016).
- 722 42. Dethlefsen, L., Huse, S., Sogin, M.L. & Relman, D.A. The pervasive effects of
723 an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA
724 sequencing. *PLoS Biol* **6**, e280 (2008).
- 725 43. Henao-Mejia, J. *et al.* Inflammasome-mediated dysbiosis regulates
726 progression of NAFLD and obesity. *Nature* **482**, 179-185 (2012).
- 727 44. Newton, D.F., Cummings, J.H., Macfarlane, S. & Macfarlane, G.T. Growth of a
728 human intestinal *Desulfovibrio desulfuricans* in continuous cultures containing
729 defined populations of saccharolytic and amino acid fermenting bacteria. *J Appl*
730 *Microbiol* **85**, 372-380 (1998).
- 731 45. Carbonero, F., Benefiel, A.C. & Gaskins, H.R. Contributions of the microbial
732 hydrogen economy to colonic homeostasis. *Nat Rev Gastroenterol Hepatol* **9**, 504-
733 518 (2012).
- 734 46. Roediger, W.E., Duncan, A., Kapaniris, O. & Millard, S. Reducing sulfur
735 compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis.
736 *Gastroenterology* **104**, 802-809 (1993).
- 737 47. Suarez, F., Furne, J., Springfield, J. & Levitt, M. Production and elimination of
738 sulfur-containing gases in the rat colon. *Am J Physiol* **274**, G727-733 (1998).
- 739 48. Cai, W.J., Wang, M.J., Ju, L.H., Wang, C. & Zhu, Y.C. Hydrogen sulfide
740 induces human colon cancer cell proliferation: role of Akt, ERK and p21. *Cell Biol Int*
741 **34**, 565-572 (2010).
- 742 49. Deplancke, B. & Gaskins, H.R. Hydrogen sulfide induces serum-independent
743 cell cycle entry in nontransformed rat intestinal epithelial cells. *FASEB J* **17**, 1310-
744 1312 (2003).
- 745 50. Attene-Ramos, M.S., Wagner, E.D., Plewa, M.J. & Gaskins, H.R. Evidence
746 that hydrogen sulfide is a genotoxic agent. *Mol Cancer Res* **4**, 9-14 (2006).

- 747 51. Kanazawa, K. *et al.* Factors influencing the development of sigmoid colon
748 cancer. Bacteriologic and biochemical studies. *Cancer* **77**, 1701-1706 (1996).
- 749 52. Kostic, A.D. *et al.* Genomic analysis identifies association of *Fusobacterium*
750 with colorectal carcinoma. *Genome Res* **22**, 292-298 (2012).
- 751 53. Castellarin, M. *et al.* *Fusobacterium nucleatum* infection is prevalent in human
752 colorectal carcinoma. *Genome Res* **22**, 299-306 (2012).
- 753 54. Yang, Y. *et al.* *Fusobacterium nucleatum* Increases Proliferation of Colorectal
754 Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4
755 Signaling to Nuclear Factor-kappaB, and Up-regulating Expression of MicroRNA-21.
756 *Gastroenterology* **152**, 851-866 e824 (2017).
- 757 55. Yu, T. *et al.* *Fusobacterium nucleatum* Promotes Chemoresistance to
758 Colorectal Cancer by Modulating Autophagy. *Cell* **170**, 548-563 e516 (2017).
- 759 56. Campisciano, G. *et al.* The Obesity-Related Gut Bacterial and Viral Dysbiosis
760 Can Impact the Risk of Colon Cancer Development. *Microorganisms* **8** (2020).
- 761 57. Feng, Q. *et al.* Gut microbiome development along the colorectal adenoma-
762 carcinoma sequence. *Nat Commun* **6**, 6528 (2015).
- 763 58. Arthur, J.C. *et al.* Intestinal inflammation targets cancer-inducing activity of the
764 microbiota. *Science* **338**, 120-123 (2012).
- 765 59. Garrett, W.S. The gut microbiota and colon cancer. *Science* **364**, 1133-1135
766 (2019).
- 767 60. Dejea, C.M. *et al.* Patients with familial adenomatous polyposis harbor colonic
768 biofilms containing tumorigenic bacteria. *Science* **359**, 592-597 (2018).
- 769 61. Zhang, G., Svenungsson, B., Karnell, A. & Weintraub, A. Prevalence of
770 enterotoxigenic *Bacteroides fragilis* in adult patients with diarrhea and healthy
771 controls. *Clin Infect Dis* **29**, 590-594 (1999).
- 772 62. Turnbaugh, P.J. *et al.* A core gut microbiome in obese and lean twins. *Nature*
773 **457**, 480-484 (2009).
- 774 63. Turnbaugh, P.J. *et al.* The effect of diet on the human gut microbiome: a
775 metagenomic analysis in humanized gnotobiotic mice. *Sci Transl Med* **1**, 6ra14
776 (2009).
- 777 64. Carmody, R.N. *et al.* Diet dominates host genotype in shaping the murine gut
778 microbiota. *Cell Host Microbe* **17**, 72-84 (2015).
- 779 65. De Filippis, F. *et al.* High-level adherence to a Mediterranean diet beneficially
780 impacts the gut microbiota and associated metabolome. *Gut* **65**, 1812-1821 (2016).

- 781 66. Donohoe, D.R. *et al.* A gnotobiotic mouse model demonstrates that dietary
782 fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-
783 dependent manner. *Cancer Discov* **4**, 1387-1397 (2014).
- 784 67. Desai, M.S. *et al.* A Dietary Fiber-Deprived Gut Microbiota Degrades the
785 Colonic Mucus Barrier and Enhances Pathogen Susceptibility. *Cell* **167**, 1339-1353
786 e1321 (2016).
- 787 68. Halmos, E.P., Power, V.A., Shepherd, S.J., Gibson, P.R. & Muir, J.G. A diet
788 low in FODMAPs reduces symptoms of irritable bowel syndrome. *Gastroenterology*
789 **146**, 67-75 e65 (2014).
- 790 69. Sanders, M.E., Merenstein, D.J., Reid, G., Gibson, G.R. & Rastall, R.A.
791 Probiotics and prebiotics in intestinal health and disease: from biology to the clinic.
792 *Nat Rev Gastroenterol Hepatol* **16**, 605-616 (2019).
- 793 70. Nami, Y., Haghshenas, B., Haghshenas, M., Abdullah, N. & Yari
794 Khosroushahi, A. The Prophylactic Effect of Probiotic *Enterococcus lactis* IW5
795 against Different Human Cancer Cells. *Front Microbiol* **6**, 1317 (2015).
- 796 71. Kaeid Sharaf, L. & Shukla, G. Probiotics (*Lactobacillus acidophilus* and
797 *Lactobacillus rhamnosus* GG) in Conjunction with Celecoxib (selective COX-2
798 inhibitor) Modulated DMH-Induced Early Experimental Colon Carcinogenesis. *Nutr*
799 *Cancer* **70**, 946-955 (2018).
- 800 72. Sharaf, L.K., Sharma, M., Chandel, D. & Shukla, G. Prophylactic intervention
801 of probiotics (*L.acidophilus*, *L.rhamnosus* GG) and celecoxib modulate Bax-mediated
802 apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis. *BMC*
803 *Cancer* **18**, 1111 (2018).
- 804 73. Li, J. *et al.* Probiotics modulated gut microbiota suppresses hepatocellular
805 carcinoma growth in mice. *Proc Natl Acad Sci U S A* **113**, E1306-1315 (2016).
- 806 74. Bajramagic, S. *et al.* Usage of Probiotics and its Clinical Significance at
807 Surgically Treated Patients Suffering from Colorectal Carcinoma. *Med Arch* **73**, 316-
808 320 (2019).
- 809 75. Azcarate-Peril, M.A., Sikes, M. & Bruno-Barcena, J.M. The intestinal
810 microbiota, gastrointestinal environment and colorectal cancer: a putative role for
811 probiotics in prevention of colorectal cancer? *Am J Physiol Gastrointest Liver Physiol*
812 **301**, G401-424 (2011).

- 813 76. Zhuo, Q. *et al.* Lysates of *Lactobacillus acidophilus* combined with CTLA-4-
814 blocking antibodies enhance antitumor immunity in a mouse colon cancer model. *Sci*
815 *Rep* **9**, 20128 (2019).
- 816 77. Eeckhaut, V. *et al.* The Probiotic *Butyricococcus pullicaecorum* Reduces Feed
817 Conversion and Protects from Potentially Harmful Intestinal Microorganisms and
818 Necrotic Enteritis in Broilers. *Front Microbiol* **7**, 1416 (2016).
- 819 78. Everard, A. *et al.* Cross-talk between *Akkermansia muciniphila* and intestinal
820 epithelium controls diet-induced obesity. *Proc Natl Acad Sci U S A* **110**, 9066-9071
821 (2013).
- 822 79. Gopalakrishnan, V. *et al.* Gut microbiome modulates response to anti-PD-1
823 immunotherapy in melanoma patients. *Science* **359**, 97-103 (2018).
- 824 80. Routy, B. *et al.* Gut microbiome influences efficacy of PD-1-based
825 immunotherapy against epithelial tumors. *Science* **359**, 91-97 (2018).
- 826 81. Zhai, R. *et al.* Strain-Specific Anti-inflammatory Properties of Two
827 *Akkermansia muciniphila* Strains on Chronic Colitis in Mice. *Front Cell Infect*
828 *Microbiol* **9**, 239 (2019).
- 829 82. Paolillo, R., Romano Carratelli, C., Sorrentino, S., Mazzola, N. & Rizzo, A.
830 Immunomodulatory effects of *Lactobacillus plantarum* on human colon cancer cells.
831 *Int Immunopharmacol* **9**, 1265-1271 (2009).
- 832 83. Kahouli, I., Malhotra, M., Westfall, S., Alaoui-Jamali, M.A. & Prakash, S.
833 Design and validation of an orally administrated active *L. fermentum*-*L. acidophilus*
834 probiotic formulation using colorectal cancer *Apc* (Min/+) mouse model. *Appl*
835 *Microbiol Biotechnol* **101**, 1999-2019 (2017).
- 836 84. Zhu, J. *et al.* *Lactobacillus salivarius* Ren prevent the early colorectal
837 carcinogenesis in 1, 2-dimethylhydrazine-induced rat model. *J Appl Microbiol* **117**,
838 208-216 (2014).
- 839 85. Chen, L. *et al.* NLRP12 attenuates colon inflammation by maintaining colonic
840 microbial diversity and promoting protective commensal bacterial growth. *Nat*
841 *Immunol* **18**, 541-551 (2017).
- 842 86. Redman, M.G., Ward, E.J. & Phillips, R.S. The efficacy and safety of
843 probiotics in people with cancer: a systematic review. *Ann Oncol* **25**, 1919-1929
844 (2014).
- 845 87. Gibson, G.R. *et al.* Expert consensus document: The International Scientific
846 Association for Probiotics and Prebiotics (ISAPP) consensus statement on the

- 847 definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol* **14**, 491-502
848 (2017).
- 849 88. van Loo, J., Coussement, P., de Leenheer, L., Hoebregs, H. & Smits, G. On
850 the presence of inulin and oligofructose as natural ingredients in the western diet. *Crit*
851 *Rev Food Sci Nutr* **35**, 525-552 (1995).
- 852 89. Roberfroid, M.B., Van Loo, J.A. & Gibson, G.R. The bifidogenic nature of
853 chicory inulin and its hydrolysis products. *J Nutr* **128**, 11-19 (1998).
- 854 90. Campbell, J.M., Fahey, G.C., Jr. & Wolf, B.W. Selected indigestible
855 oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH
856 and microflora in rats. *J Nutr* **127**, 130-136 (1997).
- 857 91. Fehlbaum, S. *et al.* In Vitro Fermentation of Selected Prebiotics and Their
858 Effects on the Composition and Activity of the Adult Gut Microbiota. *Int J Mol Sci* **19**
859 (2018).
- 860 92. Li, K. *et al.* Dietary inulin alleviates diverse stages of type 2 diabetes mellitus
861 via anti-inflammation and modulating gut microbiota in db/db mice. *Food Funct* **10**,
862 1915-1927 (2019).
- 863 93. Fuentes-Zaragoza, E. *et al.* Resistant starch as prebiotic: A review. *Starch -*
864 *Stärke* **63**, 406-415 (2011).
- 865 94. Sharma, A., Yadav, B.S. & Ritika Resistant Starch: Physiological Roles and
866 Food Applications. *Food Reviews International* **24**, 193-234 (2008).
- 867 95. Faraj, A., Vasanthan, T. & Hoover, R. The effect of extrusion cooking on
868 resistant starch formation in waxy and regular barley flours. *Food Research*
869 *International* **37**, 517-525 (2004).
- 870 96. Zheng, D.W. *et al.* Prebiotics-Encapsulated Probiotic Spores Regulate Gut
871 Microbiota and Suppress Colon Cancer. *Adv Mater* **32**, e2004529 (2020).
- 872 97. Swanson, K.S. *et al.* The International Scientific Association for Probiotics and
873 Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics.
874 *Nat Rev Gastroenterol Hepatol* **17**, 687-701 (2020).
- 875 98. Le Leu, R.K., Hu, Y., Brown, I.L., Woodman, R.J. & Young, G.P. Synbiotic
876 intervention of *Bifidobacterium lactis* and resistant starch protects against colorectal
877 cancer development in rats. *Carcinogenesis* **31**, 246-251 (2010).
- 878 99. Ganesh, K. *et al.* Immunotherapy in colorectal cancer: rationale, challenges
879 and potential. *Nat Rev Gastroenterol Hepatol* **16**, 361-375 (2019).

- 880 100. Paulos, C.M. *et al.* Microbial translocation augments the function of adoptively
881 transferred self/tumor-specific CD8+ T cells via TLR4 signaling. *J Clin Invest* **117**,
882 2197-2204 (2007).
- 883 101. Iida, N. *et al.* Commensal bacteria control cancer response to therapy by
884 modulating the tumor microenvironment. *Science* **342**, 967-970 (2013).
- 885 102. Viaud, S. *et al.* The intestinal microbiota modulates the anticancer immune
886 effects of cyclophosphamide. *Science* **342**, 971-976 (2013).
- 887 103. Vetizou, M. *et al.* Anticancer immunotherapy by CTLA-4 blockade relies on the
888 gut microbiota. *Science* **350**, 1079-1084 (2015).
- 889 104. Sivan, A. *et al.* Commensal Bifidobacterium promotes antitumor immunity and
890 facilitates anti-PD-L1 efficacy. *Science* **350**, 1084-1089 (2015).
- 891 105. Gaines, S. *et al.* Western Diet Promotes Intestinal Colonization by
892 Collagenolytic Microbes and Promotes Tumor Formation After Colorectal Surgery.
893 *Gastroenterology* **158**, 958-970 e952 (2020).
- 894 106. Chen, D.S. & Mellman, I. Elements of cancer immunity and the cancer-
895 immune set point. *Nature* **541**, 321-330 (2017).
- 896 107. Matson, V. *et al.* The commensal microbiome is associated with anti-PD-1
897 efficacy in metastatic melanoma patients. *Science* **359**, 104-108 (2018).
- 898 108. Alberda, W.J. *et al.* The Importance of a Minimal Tumor-Free Resection
899 Margin in Locally Recurrent Rectal Cancer. *Dis Colon Rectum* **58**, 677-685 (2015).
- 900 109. Manfredi, S. *et al.* Incidence and patterns of recurrence after resection for cure
901 of colonic cancer in a well defined population. *Br J Surg* **93**, 1115-1122 (2006).
- 902 110. Naxerova, K. *et al.* Origins of lymphatic and distant metastases in human
903 colorectal cancer. *Science* **357**, 55-60 (2017).
- 904 111. Fermor, B., Umpleby, H.C., Lever, J.V., Symes, M.O. & Williamson, R.C.
905 Proliferative and metastatic potential of exfoliated colorectal cancer cells. *J Natl*
906 *Cancer Inst* **76**, 347-349 (1986).
- 907 112. Shogan, B.D. *et al.* Collagen degradation and MMP9 activation by
908 *Enterococcus faecalis* contribute to intestinal anastomotic leak. *Sci Transl Med* **7**,
909 286ra268 (2015).
- 910 113. Mirnezami, A. *et al.* Increased local recurrence and reduced survival from
911 colorectal cancer following anastomotic leak: systematic review and meta-analysis.
912 *Ann Surg* **253**, 890-899 (2011).

- 913 114. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G. & Group, P. Preferred
914 reporting items for systematic reviews and meta-analyses: the PRISMA statement.
915 *PLoS Med* **6**, e1000097 (2009).
- 916 115. Shi, L. *et al.* Combining IL-2-based immunotherapy with commensal probiotics
917 produces enhanced antitumor immune response and tumor clearance. *J Immunother*
918 *Cancer* **8** (2020).
- 919 116. Arthur, J.C. *et al.* VSL#3 probiotic modifies mucosal microbial composition but
920 does not reduce colitis-associated colorectal cancer. *Sci Rep* **3**, 2868 (2013).
- 921 117. Chandel, D., Sharma, M., Chawla, V., Sachdeva, N. & Shukla, G. Isolation,
922 characterization and identification of antigenotoxic and anticancerous indigenous
923 probiotics and their prophylactic potential in experimental colon carcinogenesis. *Sci*
924 *Rep* **9**, 14769 (2019).
- 925 118. Song, H. *et al.* Pretreatment with probiotic Bifico ameliorates colitis-associated
926 cancer in mice: Transcriptome and gut flora profiling. *Cancer Sci* **109**, 666-677
927 (2018).
- 928 119. Xu, H. *et al.* Inhibitory Effects of Breast Milk-Derived *Lactobacillus rhamnosus*
929 *Probio-M9* on Colitis-Associated Carcinogenesis by Restoration of the Gut Microbiota
930 in a Mouse Model. *Nutrients* **13** (2021).
- 931 120. Chang, S.C. *et al.* A gut butyrate-producing bacterium *Butyricoccus*
932 *pullicaecorum* regulates short-chain fatty acid transporter and receptor to reduce the
933 progression of 1,2-dimethylhydrazine-associated colorectal cancer. *Oncol Lett* **20**,
934 327 (2020).
- 935 121. Hradicka, P., Beal, J., Kassayova, M., Foey, A. & Demeckova, V. A Novel
936 Lactic Acid Bacteria Mixture: Macrophage-Targeted Prophylactic Intervention in
937 Colorectal Cancer Management. *Microorganisms* **8** (2020).
- 938 122. Silveira, D.S.C. *et al.* *Lactobacillus bulgaricus* inhibits colitis-associated cancer
939 via a negative regulation of intestinal inflammation in azoxymethane/dextran sodium
940 sulfate model. *World J Gastroenterol* **26**, 6782-6794 (2020).
- 941 123. Yuan, L. *et al.* The influence of gut microbiota dysbiosis to the efficacy of 5-
942 Fluorouracil treatment on colorectal cancer. *Biomed Pharmacother* **108**, 184-193
943 (2018).
- 944 124. Chang, C.W. *et al.* *Lactobacillus casei* Variety *rhamnosus* Probiotic
945 Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a
946 Syngeneic Colorectal Cancer Model. *Front Microbiol* **9**, 983 (2018).

- 947 125. Bindels, L.B. *et al.* Increased gut permeability in cancer cachexia: mechanisms
948 and clinical relevance. *Oncotarget* **9**, 18224-18238 (2018).
- 949 126. Jacouton, E., Chain, F., Sokol, H., Langella, P. & Bermudez-Humaran, L.G.
950 Probiotic Strain *Lactobacillus casei* BL23 Prevents Colitis-Associated Colorectal
951 Cancer. *Front Immunol* **8**, 1553 (2017).
- 952 127. Gao, C. *et al.* Gut Microbe-Mediated Suppression of Inflammation-Associated
953 Colon Carcinogenesis by Luminal Histamine Production. *Am J Pathol* **187**, 2323-
954 2336 (2017).
- 955 128. Chung, E.J. *et al.* Combination of metformin and VSL#3 additively suppresses
956 western-style diet induced colon cancer in mice. *Eur J Pharmacol* **794**, 1-7 (2017).
- 957 129. da Silva Duarte, V. *et al.* Chemoprevention of DMH-Induced Early Colon
958 Carcinogenesis in Male BALB/c Mice by Administration of *Lactobacillus Paracasei*
959 DTA81. *Microorganisms* **8** (2020).
- 960 130. Mendes, M.C.S. *et al.* Microbiota modification by probiotic supplementation
961 reduces colitis associated colon cancer in mice. *World J Gastroenterol* **24**, 1995-
962 2008 (2018).
- 963 131. Zhang, S.L. *et al.* Pectin supplement significantly enhanced the anti-PD-1
964 efficacy in tumor-bearing mice humanized with gut microbiota from patients with
965 colorectal cancer. *Theranostics* **11**, 4155-4170 (2021).
- 966 132. Li, Y. *et al.* Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth.
967 *Cell Rep* **30**, 1753-1766 e1756 (2020).
- 968 133. Zhu, L.Q. *et al.* Evodiamine inhibits high-fat diet-induced colitis-associated
969 cancer in mice through regulating the gut microbiota. *J Integr Med* **19**, 56-65 (2021).
- 970 134. Terasaki, M. *et al.* Alteration of fecal microbiota by fucoxanthin results in
971 prevention of colorectal cancer in AOM/DSS-treated mice. *Carcinogenesis* (2020).
- 972 135. Luo, L. *et al.* The effect of menthol supplement diet on colitis-induced colon
973 tumorigenesis and intestinal microbiota. *Am J Transl Res* **13**, 38-56 (2021).
- 974 136. Liu, X., Wang, L., Jing, N., Jiang, G. & Liu, Z. Biostimulating Gut Microbiome
975 with Bilberry Anthocyanin Combo to Enhance Anti-PD-L1 Efficiency against Murine
976 Colon Cancer. *Microorganisms* **8** (2020).
- 977 137. Zhang, H., Hui, D., Li, Y., Xiong, G. & Fu, X. Canmei Formula Reduces Colitis-
978 Associated Colorectal Carcinogenesis in Mice by Modulating the Composition of Gut
979 Microbiota. *Front Oncol* **9**, 1149 (2019).

- 980 138. Khan, I. *et al.* Mushroom polysaccharides and jiaogulan saponins exert cancer
981 preventive effects by shaping the gut microbiota and microenvironment in Apc(Min/+)
982 mice. *Pharmacol Res* **148**, 104448 (2019).
- 983 139. Li, S., Fu, C., Zhao, Y. & He, J. Intervention with alpha-Ketoglutarate
984 Ameliorates Colitis-Related Colorectal Carcinoma via Modulation of the Gut
985 Microbiome. *Biomed Res Int* **2019**, 8020785 (2019).
- 986 140. Fernandez, J. *et al.* A Galacto-Oligosaccharides Preparation Derived From
987 Lactulose Protects Against Colorectal Cancer Development in an Animal Model.
988 *Front Microbiol* **9**, 2004 (2018).
- 989 141. Mudd, A.M. *et al.* Chemoprevention of Colorectal Cancer by Anthocyanidins
990 and Mitigation of Metabolic Shifts Induced by Dysbiosis of the Gut Microbiome.
991 *Cancer Prev Res (Phila)* **13**, 41-52 (2020).
- 992 142. Wu, J.C. *et al.* Polymethoxyflavones prevent benzo[a]pyrene/dextran sodium
993 sulfate-induced colorectal carcinogenesis through modulating xenobiotic metabolism
994 and ameliorate autophagic defect in ICR mice. *Int J Cancer* **142**, 1689-1701 (2018).
- 995 143. Wang, X. *et al.* Structural shift of gut microbiota during chemo-preventive
996 effects of epigallocatechin gallate on colorectal carcinogenesis in mice. *World J*
997 *Gastroenterol* **23**, 8128-8139 (2017).
- 998 144. Chou, Y.C. *et al.* Boswellia serrata resin extract alleviates azoxymethane
999 (AOM)/dextran sodium sulfate (DSS)-induced colon tumorigenesis. *Mol Nutr Food*
1000 *Res* **61** (2017).
- 1001 145. Fukuda, M. *et al.* Prebiotic treatment reduced preneoplastic lesions through
1002 the downregulation of toll like receptor 4 in a chemo-induced carcinogenic model. *J*
1003 *Clin Biochem Nutr* **49**, 57-61 (2011).
- 1004 146. Oh, N.S., Lee, J.Y., Kim, Y.T., Kim, S.H. & Lee, J.H. Cancer-protective effect
1005 of a synbiotic combination between *Lactobacillus gasseri* 505 and a *Cudrania*
1006 *tricuspidata* leaf extract on colitis-associated colorectal cancer. *Gut Microbes* **12**,
1007 1785803 (2020).
- 1008 147. Rudd, D.A. *et al.* Mapping insoluble indole metabolites in the gastrointestinal
1009 environment of a murine colorectal cancer model using desorption/ionisation on
1010 porous silicon imaging. *Sci Rep* **9**, 12342 (2019).
- 1011 148. Zhang, J. *et al.* A Functional Food Inhibits Azoxymethane/Dextran Sulfate
1012 Sodium-Induced Inflammatory Colorectal Cancer in Mice. *Onco Targets Ther* **14**,
1013 1465-1477 (2021).

- 1014 149. Piazzi, G. *et al.* A Mediterranean Diet Mix Has Chemopreventive Effects in a
1015 Murine Model of Colorectal Cancer Modulating Apoptosis and the Gut Microbiota.
1016 *Front Oncol* **9**, 140 (2019).
- 1017 150. Li, F. *et al.* Modulation of colon cancer by nutmeg. *J Proteome Res* **14**, 1937-
1018 1946 (2015).
- 1019 151. Chen, L. *et al.* Chemoprevention of colorectal cancer by black raspberry
1020 anthocyanins involved the modulation of gut microbiota and SFRP2 demethylation.
1021 *Carcinogenesis* **39**, 471-481 (2018).
- 1022 152. Fernandez, J., Garcia, L., Monte, J., Villar, C.J. & Lombo, F. Functional
1023 Anthocyanin-Rich Sausages Diminish Colorectal Cancer in an Animal Model and
1024 Reduce Pro-Inflammatory Bacteria in the Intestinal Microbiota. *Genes (Basel)* **9**
1025 (2018).
- 1026 153. Wang, C.Z. *et al.* Role of intestinal microbiome in American ginseng-mediated
1027 colon cancer prevention in high fat diet-fed AOM/DSS mice [corrected]. *Clin Transl*
1028 *Oncol* **20**, 302-312 (2018).
- 1029 154. Hu, Y. *et al.* Manipulation of the gut microbiota using resistant starch is
1030 associated with protection against colitis-associated colorectal cancer in rats.
1031 *Carcinogenesis* **37**, 366-375 (2016).
- 1032 155. Yu, C. *et al.* American ginseng significantly reduced the progression of high-
1033 fat-diet-enhanced colon carcinogenesis in Apc (Min/+) mice. *J Ginseng Res* **39**, 230-
1034 237 (2015).
- 1035 156. Gao, Z. *et al.* Probiotics modify human intestinal mucosa-associated
1036 microbiota in patients with colorectal cancer. *Mol Med Rep* **12**, 6119-6127 (2015).
- 1037 157. Zhang, J.W. *et al.* Preoperative probiotics decrease postoperative infectious
1038 complications of colorectal cancer. *Am J Med Sci* **343**, 199-205 (2012).
- 1039 158. Aisu, N. *et al.* Impact of perioperative probiotic treatment for surgical site
1040 infections in patients with colorectal cancer. *Exp Ther Med* **10**, 966-972 (2015).
- 1041 159. Liu, Z. *et al.* Randomised clinical trial: the effects of perioperative probiotic
1042 treatment on barrier function and post-operative infectious complications in colorectal
1043 cancer surgery - a double-blind study. *Aliment Pharmacol Ther* **33**, 50-63 (2011).
- 1044 160. Gianotti, L. *et al.* A randomized double-blind trial on perioperative
1045 administration of probiotics in colorectal cancer patients. *World J Gastroenterol* **16**,
1046 167-175 (2010).

- 1047 161. So, W.K.W. *et al.* Effects of a Rice Bran Dietary Intervention on the
1048 Composition of the Intestinal Microbiota of Adults with a High Risk of Colorectal
1049 Cancer: A Pilot Randomised-Controlled Trial. *Nutrients* **13** (2021).
- 1050 162. Xie, X. *et al.* Effects of prebiotics on immunologic indicators and intestinal
1051 microbiota structure in perioperative colorectal cancer patients. *Nutrition* **61**, 132-142
1052 (2019).
- 1053 163. Polakowski, C.B., Kato, M., Preti, V.B., Schieferdecker, M.E.M. & Ligocki
1054 Campos, A.C. Impact of the preoperative use of synbiotics in colorectal cancer
1055 patients: A prospective, randomized, double-blind, placebo-controlled study. *Nutrition*
1056 **58**, 40-46 (2019).
- 1057 164. Hibberd, A.A. *et al.* Intestinal microbiota is altered in patients with colon cancer
1058 and modified by probiotic intervention. *BMJ Open Gastroenterol* **4**, e000145 (2017).
- 1059 165. Worthley, D.L. *et al.* A human, double-blind, placebo-controlled, crossover trial
1060 of prebiotic, probiotic, and synbiotic supplementation: effects on luminal,
1061 inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer. *Am J Clin*
1062 *Nutr* **90**, 578-586 (2009).
- 1063 166. Brown, D.G., Borresen, E.C., Brown, R.J. & Ryan, E.P. Heat-stabilised rice
1064 bran consumption by colorectal cancer survivors modulates stool metabolite profiles
1065 and metabolic networks: a randomised controlled trial. *Br J Nutr* **117**, 1244-1256
1066 (2017).
- 1067 167. Nunez-Sanchez, M.A. *et al.* Gene expression changes in colon tissues from
1068 colorectal cancer patients following the intake of an ellagitannin-containing
1069 pomegranate extract: a randomized clinical trial. *J Nutr Biochem* **42**, 126-133 (2017).
- 1070 168. Nunez-Sanchez, M.A. *et al.* MicroRNAs expression in normal and malignant
1071 colon tissues as biomarkers of colorectal cancer and in response to pomegranate
1072 extracts consumption: Critical issues to discern between modulatory effects and
1073 potential artefacts. *Mol Nutr Food Res* **59**, 1973-1986 (2015).
- 1074 169. Chen, C.C. *et al.* Oral inoculation of probiotics *Lactobacillus acidophilus* NCFM
1075 suppresses tumour growth both in segmental orthotopic colon cancer and extra-
1076 intestinal tissue. *Br J Nutr* **107**, 1623-1634 (2012).
- 1077 170. Bellville, J.W., Swanson, G.D., Miyake, T. & Aqleh, K.A. Respiratory
1078 stimulation observed following ethanol ingestion. *West J Med* **124**, 423-425 (1976).

- 1079 171. Shinohara, K., Ohashi, Y., Kawasumi, K., Terada, A. & Fujisawa, T. Effect of
1080 apple intake on fecal microbiota and metabolites in humans. *Anaerobe* **16**, 510-515
1081 (2010).
- 1082 172. Schwartz, S.E. *et al.* Sustained pectin ingestion: effect on gastric emptying
1083 and glucose tolerance in non-insulin-dependent diabetic patients. *Am J Clin Nutr* **48**,
1084 1413-1417 (1988).
- 1085 173. Annunziata, G. *et al.* Effect of Grape Pomace Polyphenols With or Without
1086 Pectin on TMAO Serum Levels Assessed by LC/MS-Based Assay: A Preliminary
1087 Clinical Study on Overweight/Obese Subjects. *Front Pharmacol* **10**, 575 (2019).
- 1088 174. Glinsky, V.V. & Raz, A. Modified citrus pectin anti-metastatic properties: one
1089 bullet, multiple targets. *Carbohydr Res* **344**, 1788-1791 (2009).
- 1090 175. Warburg, O. On the origin of cancer cells. *Science* **123**, 309-314 (1956).
- 1091 176. Roediger, W.E. Role of anaerobic bacteria in the metabolic welfare of the
1092 colonic mucosa in man. *Gut* **21**, 793-798 (1980).
- 1093 177. Khoo, H.E., Azlan, A., Tang, S.T. & Lim, S.M. Anthocyanidins and
1094 anthocyanins: colored pigments as food, pharmaceutical ingredients, and the
1095 potential health benefits. *Food Nutr Res* **61**, 1361779 (2017).
- 1096 178. Reglero, C. & Reglero, G. Precision Nutrition and Cancer Relapse Prevention:
1097 A Systematic Literature Review. *Nutrients* **11** (2019).
- 1098 179. Toledo, E. *et al.* Mediterranean Diet and Invasive Breast Cancer Risk Among
1099 Women at High Cardiovascular Risk in the PREDIMED Trial: A Randomized Clinical
1100 Trial. *JAMA Intern Med* **175**, 1752-1760 (2015).
- 1101 180. Bamia, C. *et al.* Mediterranean diet and colorectal cancer risk: results from a
1102 European cohort. *Eur J Epidemiol* **28**, 317-328 (2013).
- 1103 181. (2018).
- 1104 182. Henderson, A.J. *et al.* Chemopreventive properties of dietary rice bran: current
1105 status and future prospects. *Adv Nutr* **3**, 643-653 (2012).
- 1106
1107
1108
1109
1110
1111
1112
1113
1114
1115

1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132

1133 **Figure legends**

1134

1135 **Figure 1. Flow chart of the search and selection process.**

1136

1137 **Figure 2. Distribution of the studies analyzed. a.** Preclinical and clinical studies. **b**
1138 **and c.** Pre-, pro-, symbiotics and food in **b.** preclinical and **c.** clinical studies. **d.**
1139 Strains used as probiotics in preclinical studies. **e.** Prebiotics used in preclinical
1140 studies. **f.** Strains used as probiotics in clinical studies. **g.** Prebiotics used in clinical
1141 studies. * More than 1 pro- and prebiotic is used in some studies.

1142

1143

1144

1145

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166

Table 1. Details of the search strategy used.

Field	Key words	Boolean Operator
Title	(Cancer* OR carcino* OR tumor* OR onco*)	AND
Title/Abstract	(colon* OR colorect*)	AND
Title/Abstract	(microbi* OR dysbi*)	AND
Title/Abstract	(chemo* OR immuno* OR car-t* OR radium* OR surgery* OR therapy*)	AND
Title/Abstract	(nutrition* OR diet* OR food* OR probio* OR prebio* OR symbio*)	NOT
Type of publication	(Biography OR Comment OR Duplicate publication OR Editorial OR Guideline OR Interview OR News OR Personal Narrative OR Published Erratum OR Retracted Publication OR Retraction of Publication OR Meta-Analysis OR Review OR Systematic Review)	

Using words/prefixes with an asterisk opens the search to more results based on plurals and varying suffixes.

1167

Table 2. Summary of the results of the articles analyzed.

Intervention	Type of cancer	Type of study	Impact on microbiota	Mechanism	Effect on the tumor	Ref	Scientific quality
Preclinical studies							
Probiotics							
Probiotic: <i>Akkermansia muciniphila</i>	Subcutaneous, syngeneic model of colon cancer	Female BALB/c mice injected subcutaneously with CT26 cells in combination or not with IL-2	↑ diversity and <i>Akkermansia</i> , <i>Allstipes</i> and <i>Lactobacillus</i>	↑ necrosis, ↓ proliferation, and ↑ tumor apoptosis. ↑ CTL and ↓ Treg recruitment. ↑ IFN-γ and IL-2 in the tumor and ↑ TNF-α in serum, together with ↓ TGF-β. The Amuc protein effects through TLR2.	↓ tumor volume and weight and ↑ survival time	115	4
Probiotic: VSL#3, is composed of: <i>Lactobacillus plantarum</i> , <i>Lactobacillus delbrueckii</i> subsp. <i>Bulgaricus</i> , <i>Lactobacillus paracasei</i> , <i>Lactobacillus acidophilus</i> , <i>Bifidobacterium breve</i> , <i>Bifidobacterium longum</i> , <i>Bifidobacterium infantis</i> and <i>Streptococcus salivarius</i> subsp. <i>Thermophilus</i> .	Gnobioc model of CRC associated with colitis and inflammation	129/SvEv deficient in IL10 treated with AOM	↓ <i>Verrucomicrobia</i> and ↑ <i>Proteobacteria</i> in the mucosa. ↓ <i>Bacteroidetes</i> in feces	↓ <i>Clostridium</i> in the mucous membrane	↑ penetrance, invasiveness, histological grade, tumor volume and number of tumors	116	4
Inactivated	CRC	Syngeneic	↓ <i>Proteobacteria</i>		↓ of tumors	76	3

probiotic: <i>Lactobacillus acidophilus</i> lysates (<i>Phylum Firmicutes</i>)	associated with colitis	male BALB/C treated with AOM and DSS		↑ Th1 lymphocytes (CD3 + CD4 + IFN-γ+) and M1 macrophages (CD11b + F4/80 + CD86+) in mesenteric lymphoid nodules. In combination with anti CTLA-4 ↑ TCD8+ effector memory (CD44 + CD8 + CD62L+), ↓ Treg (CD4 + CD25 + Foxp3+) and M2 macrophages (F4/80 + CD206+) in the tumor microenvironment. In addition to ↑ IL-2 in nodules and plasma and plasma IFN-γ	and trend towards ↑ survival in combination with CTLA-4 inhibitors		
Probiotic: <i>Lactobacillus rhamnosus</i> , <i>Lactobacillus plantarum</i> and <i>Pediococcus pentosaceus</i>	Early colon carcinogenesis	Male Wistar rats treated with DHM	↑ lactic acid bacteria	↓ weight loss, fecal pH, liver transaminases and fecal enzyme normalization	↓ aberrant intestinal crypts, especially with <i>L. rhamnosus</i> .	117	3
Probiotic: <i>Enterococcus faecalis</i> , <i>Bifidobacterium longum</i> and <i>Lactobacillus acidophilus</i> (Bifico)	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ <i>Lactobacillus</i> . ↓ <i>Desulfovibrio</i> , <i>Mucispirillum</i> , and <i>Odoribacter</i>	↑ colon size. ↓ IL-1β, IL-6, COX-2 and TNF-α, in addition to PGE2 production. ↓ Cxcl1, Cxcl2, Cxcl3, Cxcl5 and Ccl7.	↓ number and volume of tumors	118	3
Probiotic: <i>Akkermansia muciniphila</i> or its specific membrane protein Amuc_1100	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	NR	↑ cytotoxic TCD8 in mesenteric nodules. ↑ TCD8-TNF-α+ and ↓ TCD8-PD-1+. ↓ TCD8 and Ki67 in colon.	↓ malignancy score, tumor formation and area	36	2
Probiotic: <i>Lactobacillus rhamnosus M9</i>	CRC associated with colitis	Male 6-C57BL/6NCRSc mice treated with AOM and DSS	↑ diversity of the flora and ↑ of <i>Blautia</i> , <i>Akkermansia</i> , <i>Lactobacillus</i> and <i>Bifidobacterium</i>	↓ PCNA, pSTAT3, pAKT. ↓ CD68+ and CD163+ in subserosa.	↓ number and size of tumors. ↓ inflammatory and fibrotic score.	119	2
Probiotic: <i>Butyricoccus pullicaecorum</i>	CRC associated with colitis	male BALB/cByJNarl treated with DHM	NR	↑ SLC5A8 and GPR43	↓ infiltration, anal bleeding, and CEA levels	120	2

<p>Probiotic: <i>Lactobacillus plantarum</i> VD23 <i>Lactobacillus plantarum</i> C28 <i>Lactobacillus plantarum</i> MS18 <i>Lactobacillus salivarius</i> MS3 <i>Lactobacillus salivarius</i> MS6 <i>Lactobacillus salivarius</i> MS16</p>	Early colon carcinogenesis	Male Wistar rats treated with DHM	NR	↑IL-18	↓ proliferation, volume and total number of tumors. ↑ colon length (non-significant results)	121	2
<p>Probiotic: <i>Lactobacillus bulgaricus</i></p>	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	NR	↓ IL-6, TNF-α, IL-17, IL-23 and IL-1β and ↑ IFN-γ in healthy and tumor intestinal tissue	↓ mean tumor volume and size. ↓ pathological severity score and ↑ colon length.	122	2
<p>Probiotic: <i>Bifidobacterium</i> and <i>Lactobacillus</i></p>	Subcutaneous, syngeneic model of colon cancer	Female BALB/c mice injected subcutaneously with CT26 cells	<p>↑ <i>Alloprebotella</i>, <i>Citrobacter</i>, <i>Prevotellaceae_UCG-001</i>, <i>Roseburia</i>, <i>Thalassospira</i>, <i>Erysipelatoclostridium</i> and <i>Lachnospiraceae_UCG-006</i>. ↓ <i>Desulfovibrio</i>, <i>Anaerotruncus</i>, <i>Mucispirillum</i>, <i>Odoribacter</i>. and <i>Escherichia-Shigella</i>.</p> <p>↑ <i>Bacteroides_chinchillae</i> and <i>Helicobacter_Ganmani</i>. ↓ <i>Escherichia coli</i>, <i>Lachnospiraceae_bacterium_COE1</i>, <i>Bacteroides vulgatus</i> and <i>Lachnospiraceae_bacterium_10-1</i></p>	NR	No change in tumor volume	123	2
<p>Probiotic: <i>Lactobacillus casei</i> variety <i>rhamnosus</i> (<i>Lcr35</i>)</p>	Subcutaneous, syngeneic model of colon cancer	Male BALB/c mice injected subcutaneously with CT26 cells and treated with FOLFOX (5-fluorouracil, leucovorin, and Lactobacillus casei oxaliplatin).	↑ <i>Firmicutes</i> and <i>Bacteroidetes</i>	↓ severe diarrhea and mucositis. ↓ apoptotic cells, NF-κB and BAX. ↓ TNF-α and IL6.	Unchanged	124	2
<p>Probiotic: <i>Faecalibacterium prausnitzii</i></p>	Subcutaneous model, colon cancer with cachexia	Male CD2F1 mice injected subcutaneously with C26 (I understand this refers to CT26, although it is	NR	Improvement of various parameters related to the intestinal barrier, but not significant	↓ tumor mass, not significant	125	2

		not specified).					
Probiotic: <i>Lactobacillus casei</i> BL23	CRC associated with colitis	C57BL/6 WT females treated with AOM and DSS	↑ <i>Lactobacillus zeae</i>	↓ Ki67. ↑ Bik	↓ tumor volume, number of tumors and histological malignancy	126	2
Probiotic: <i>Lactobacillus reuteri</i>	CRC associated with colitis	Hdc ^{-/-} BALB/c male BALB/c treated with AOM and DSS	NR	↓ tumor zone KC, IL22, IL6, TNF-α, IL-1-α. ↓ serum KC, IL22, IL6. ↓ CD11b+Gr-1+	↓ number of tumors	127	2
Probiotic: VSL#3, is composed of: <i>Lactobacillus plantarum</i> , <i>Lactobacillus delbrueckii</i> subsp. <i>Bulgaricus</i> , <i>Lactobacillus paracasei</i> , <i>Lactobacillus acidophilus</i> , <i>Bifidobacterium breve</i> , <i>Bifidobacterium longum</i> , <i>Bifidobacterium infantis</i> and <i>Streptococcus salivarius</i> subsp. <i>Thermophilus</i> .	CRC associated with colitis	Male BALB/c WT treated with AOM and DSS with Western diet and metformin.	NR	Metformin + VSL#3 = ↓ Ki67, F4/80	Metformin and metformin+VSL#3 = ↓ number of tumors	128	2
Probiotic: <i>Lactobacillus paracasei</i> DTA81	Early colon carcinogenesis	male BALB/c WT treated with DHM	↑ <i>Ruminiclostridium</i> and ↑ fecal acetic acid* and short-chain short acids* (*poorly performed comparator groups)	↓ IL-6, IL-17, and PCNA in colonic homogenates	Show no change	129	1
Probiotic: <i>Lactobacillus rhamnosus</i>	Early colon carcinogenesis	male BALB/c WT treated with DHM	↑ <i>Romboutsia</i> and <i>Turicibacter</i>	↑ IL4, IL-10 IL-6, IL-17, TNF-α, IFN-γ, c-MYC and P-53 in colonic homogenates	Show no change	129	1
Probiotics: <i>Lactobacillus acidophilus</i> , <i>Lactobacillus rhamnosus</i> and <i>Bifidobacterium bifidum</i>	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ <i>Lactobacillus</i> , <i>Bifidobacterium</i> , <i>Allobaculum</i> , <i>Clostridium XI</i> , and <i>Clostridium X III</i>	↓ colitis, ↓ circulating levels of RANTES and eotaxin; ↓ p-IKK and TNF-α with ↑ IL-10	↓ incidence and number of tumors	130	1
Prebiotics							
Prebiotic: Fructooligosaccharide/inulin	Gnobioc model of CRC associated with colitis	BALB/C mice (gender undefined) treated with AOM and DSS	NR	↑ histone 3 and ↓ HDAC activity. ↑ levels of Fas and active caspase 3. ↓ of p21, p27 and Ki-67.	↓ histological grade, volume and number of tumors	66	5

Prebiotic: Pectin	Subcutaneous, syngeneic model of colon cancer	Female C57BL/6 WT mice injected with MC38 cells. With humanized microbiota from healthy humans or patients, anti-PD-1 treatment.	↑ diversity, ↑ <i>Lactobacillaceae</i> , <i>Bifidobacteriaceae</i> , <i>Erysipelotrichaceae</i> , <i>Ruminococcaceae</i> , <i>Faecalibacterium</i> , and <i>Holdemania</i> . ↑ percentage <i>Firmicutes/Bacteroidetes</i> . ↑ acetate and butyrate.	↑ TCD4+, TCD8+ and TCD8+IFN γ + tumor infiltration	↓ tumor volume and size	131	4
Prebiotic: Mucin and inulin	Subcutaneously transplanted colon cancer (MC-38)	Syngeneic C57BL/6 mice	↑ <i>Clostridium</i> cluster XIVa	↑ of MHC class I and MHC class II expression in CD	Inulin causes ↓ tumor volume. No change in tumor volume with Mucin	132	4
Prebiotic: food extract: Evodiamine	CRC associated with colitis	C57BL/6 WT treated with HFD, AOM and DSS	↑ <i>Campylobacter</i> , <i>Bifidobacterium</i> and <i>Lactobacillus</i> . ↓ <i>E. faecalis</i> and <i>E. coli</i>	↓ IL-1, IL-6 and circulating TNF- α and in colonic tissue ↓ p-STAT3 and p-P65	↑ survival, ↓ tumor diameter and percentage weight/length of intestine. ↓ pathological score and proliferation, ↑ apoptosis.	133	3
Prebiotic: Food extract: Fucoxanthin	CRC associated with colitis	ICR WT male treated with AOM and DSS	↑ Lachnospiraceae and ↓ <i>Bacteroidales</i> and <i>Rikenellaceae</i>	↑ caspase 3	↓ size and number of colorectal adenomas and total tumors	134	3
Prebiotic: Food extract: Menthol	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ in butyrate-producing bacteria (<i>Allobaculum</i> , <i>Roseburia</i> and <i>Intestinimonas</i>) and fecal ↑ butyrate	↓ expression of β -catenin, Ki67, IL-6, TNF- α and MPO. ↓ infiltration of immune cells in the spleen, ↑ IL10 in the distal colon	↓ the number of 1-3 mm adenomas in a dose-dependent manner and damage scales.	135	2
Prebiotic: Chitosan and low molecular weight citrus pectins encapsulating bilberry anthocyanins	Subcutaneously transplanted colon cancer (MC-38)	Female C57BL/6 mice	↑ <i>Lachnospiraceae</i> (Clostridiales) and diversity	They suggest a ↑ of SCFA and TCD4+ and TCD8+ infiltration of the tumor, but are not significant.	↓ tumor volume in combination with PD-L1 inhibitors.	136	2
Prebiotic: Canmei formula	CRC associated with colitis	C57BL/6 WT females treated with AOM and DSS and HFD	↑ <i>Turicibacter</i> , <i>Bacteroides</i> , <i>Bacteroidaceae</i> , <i>Faecalibaculum</i> , <i>Erysipelatoclostridium</i> and <i>Staphylococcus</i>	↓ serum levels of IL-17 and NF- κ B	↓ tumor incidence	137	2
Prebiotic: Polysaccharides from <i>Ganoderma lucidum</i> and saponin from	Prevention of colon cancer of genetic origin	ApcMin+/- male mice	↑ bacteria producing SCFA and ↓ of sulfur-reducing bacteria	Shift from M1 to M2 macrophages. Reversal of expression, E-cadherin/N-	↓ number and size of polyp	138	2

<i>Gynostemma pentaphyllum</i>				cadherin ratio and ↓ oncogenic signaling. ↑ signaling of Gprotein coupled-receptors due to modulation of histone deacetylases, PYY and PPAR γ expression.			
Prebiotic α -ketoglutarate	CRC associated with colitis	C57BL/6 WT females treated with AOM and DSS	↑ diversity. ↑ <i>Akkermansia</i> , <i>Butyricoccus</i> , <i>Clostridium</i> and <i>Ruminococcus</i> . ↓ <i>Escherichia</i> and <i>Enterococcus</i> .	↓ IL-6, IL-22, TNF- α , and IL-1 β	↓ tumor frequency, size, and stage.	139	2
Prebiotic: Lactulose-derived galactooligosaccharides	CRC associated with colitis	Male <i>Rattus norvegicus</i> F344 rats treated with AOM and DSS	↑ propionate. ↑ diversity of flora, anti-inflammatory: <i>Bifidobacterium</i> , <i>Bacteroidaceae</i> , <i>Prevotellaceae</i> , <i>Acidaminococcaceae</i> , <i>Bifidobacteriaceae</i> , <i>Peptococcaceae</i> , <i>Oscillospiraceae</i> and ↓ of pro-inflammatory: <i>Lachnospiraceae</i> , <i>Eubacteriaceae</i> , <i>Acholeplasmataceae</i> and <i>Firmicutes/Bacteroidetes</i> %.	↑ cecum length	↓ number and volume of polyps	140	2
Prebiotic: Anthocyanidins wrapped or not in exosomes.	CRC associated with dysbiosis	ApcMin/+ Mice Inoculated with <i>Bacteroides fragilis</i>	NR	↑ in the liver, but not in the tumor, of phase I enzymes CYP1A1 and CYP1B1 and ↓ of phase II enzymes GSTM1 and SULT1	↓ number of tumors	141	1
Prebiotic: polymethoxyflavones	CRC associated with colitis	ICR WT males treated with benzo[a]pyrene and DSS	↑ <i>Sphingobacteriaceae</i> , <i>Gammaproteobacteria</i> , <i>Ruminococcaceae</i> and <i>Blautia</i> . ↓ <i>Bacilli</i> , <i>Parabacteroides</i> , <i>Lactobacillus Ruminis</i> (without statistical analysis)	↑ colon size. ↓ hepatic and renal toxicity. ↓ BaP-7,8-dihydrodiol-9,10-epoxide-DNA binding. ↓ genes for inflammation, metastasis and ↑ antioxidants.	↓ hyperplasias, adenoma and adenocarcinomas	142	1
Prebiotic: Epigallocatechin gallate (EGCG)	CRC associated with colitis	FVB/N WT female treated with benzo[a]pyrene and DSS	↑ <i>Lactobacillus</i> , <i>Fusobacterium</i> , <i>Ruminococcus</i> , ↓ <i>Bacteroides</i> , <i>Anaerotruncus</i>	NR	↓ volume and number of tumors and precancerous lesions	143	1
Prebiotic: <i>Boswellia</i>	CRC associated	ICR WT male treated with	↑ <i>Clostridiales spp</i> and ↓ <i>Bacteroidales</i>	↓ NF- κ B, PCNA. ↑	↓ number of tumors	144	1

<i>serrata</i> resin extract	with colitis	AOM and DSS		colon length			
Prebiotic: Germinated barley extract	CRC associated with colitis	AOM-treated male Fisher 344 rats	NR	↓ TLR4 and COX2	↓ aberrant crypts	145	1
Symbiotics							
Symbiotic: <i>Clostridium butyricum</i> and prebiotic dextran	Subcutaneous and orthotopic model of colon cancer	CT26Luc and ApcMin+/-	↑ <i>Muribaculaceae</i> , <i>Bacteroides</i> , <i>Mucispirillum</i> , <i>Alloprevotella</i> , <i>Lachnospiraceae</i> , and <i>Ruminococcaceae</i>	↑ iso-butyrate, butyrate, isovalerate, propionate, valerate, isohexanoate, and hexanoate, ↓ dysbiosis	↑ effectiveness of capecitabine and diclofenac, ↓ tumor size of 74% /in combination with diclofenac, while diclofenac only 11%, abdominal invasion, ↑ apoptosis	96	5
Symbiotic: <i>Lactobacillus gasseri</i> 505 (LG) and leaf extract of <i>Cudrania tricuspidata</i> (CT) in fermented milk called FCT	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ <i>Lactobacillus</i> , <i>Bifidobacterium</i> , and <i>Akkermansia</i> associated with ↑ SCFA and ↓ <i>Staphylococcus</i>	↓ TNF-α, IFN-γ, IL-1β, IL-6, iNOS and COX-2. ↑ IL-4 and IL-10. ↑ MUC2, TFF3 and ZO-1. ↑ p53, p21, and Bax. ↓ Bcl-2 and Bcl-xL. ↓ β-Catenin, NF-κB and ↑ IκB-α	↓ incidence of tumors and dysplasia. ↑ colon length	146	3
Food							
Western diet, antibiotics and <i>Enterococcus faecalis</i> .	Model of CRC recurrence after surgery	Male BALB/c mice inoculated with CT26 after resection and anastomosis	Western diet = ↑ <i>E. faecalis</i> . Western diet associated with tumors ↑ <i>Proteus</i> , <i>Akkermansia</i> and <i>Trabulsiella</i> . ↓ in <i>Bacteroides</i> , <i>Roseburia</i> and <i>Ruminococcus</i> . Inoculation with <i>E. faecalis</i> = ↑ <i>Proteus</i> , <i>Enterococcus</i> , <i>Trabulsiella</i> <i>Akkermansia</i> and <i>Clostridium</i> and ↓ <i>Roseburia</i> .	NR	↑ tumor formation with Western diet and <i>E. faecalis</i> . ↑ distant metastasis with Western diet (not significant).	105	4
Food extract: selfish <i>Muricidae</i> : 1. marine extract (NE) 2. metabolite of the extract 6-bromoisatin (6-Br)	CRC genotoxic	AOM-treated male C57BL/6 WT	NR	6-Br = ↓ tumor proliferation. NE = ↓ proliferation and ↑ apoptosis in crypts.	6-Br = ↓ number of aberrant crypts and tumors. NE = ↓ number of tumors	147	4
Functional food: extract of 55 different foodstuffs mixed	CRC associated with colitis	AOM- and DSS-treated male BALB/c mice	↓ <i>Desulfovibrio</i> and <i>Ruminococcaceae</i> and ↑ from <i>Bacteroides</i> , <i>Ruminiclostridium_6</i> , <i>Holdemanella</i> , <i>Clostridium_sensu_</i>	Improved intestinal barrier and body weight maintenance. ↓ IL-6 and TNF-α. ↑ in	↓ number and size of tumors. ↑ survival	148	3

			<i>stricto_1</i> , <i>Allobaculum</i> and <i>Parasutterella</i> . ↓ of deuteroporphylin IX, citrulline, and diferuloylputrescine, and ↑-acid acetic, ascorbic, palmitic, quinic, ursocholic, branched amino acids, rosmaridiphenol and scillirosidine	the proportion of total T cells, CD3+CD4+, CD3+CD8+, and IFN-γ-producing CD4+ T cells.			
Diet: - low fat (LFD) - high fat (HFD) - a mixture of one of them with Mediterranean (MD). This being a mixture of ω-3 polyunsaturated fatty acids (PUFA), eicosapentanoic acid and polyphenols.	CRC genotoxic	A/J WT male treated with AOM	MD improves dysbiosis with an HFD, but worsens it with an LFD.	MD ↑ apoptosis in HFD, and especially in LFD. MD ↑ eicosapentanoic acid (EPA), especially in LFD.	MD ↓ incidence in HFD, but especially in LFD	149	3
Food extract: Nutmeg	Prevention of colon cancer of genetic origin	C57BL/6J WT and ApcMin+/- Male Mice	NR	↓ in urine of cresol sulphate and glucuronide, indoxyl sulphate and phenyl sulphate. ↓ colon and liver IL6. ↓ ALT and amylase. ↑ LPE 18:0, LPC 18:0, azelaic acid, sebacic acid, palmitolcarnitine and oleocarnitine. ↑ lipid metabolism gene expression in the colon and liver	↓ tumor volume and number of tumors	150	3
Food extract: Anthocyanin extract from blackberries.	CRC associated with colitis	C57BL/6 male WT treated with AOM and DSS	↑ <i>Eubacterium rectale</i> , <i>Faecalibacterium prausnitzii</i> and <i>Lactobacillus</i> . ↓ <i>Desulfovibrio</i> and <i>Enterococcus</i> spp.	↑ SFRP2 triggers the ↓ of DNMT1 and p-STAT3. In addition to ↓ IL-1β, IL-6, IL-10, COX-2 and TNF-α.	↓ number of tumors	151	2
Food extract: Anthocyanins extracted from strawberries and blackberries	CRC associated with colitis	Male <i>Rattus norvegicus</i> F344 rats treated with AOM and DSS	↓ <i>Bilophila wadsworthia</i>	Improved plasma reducing capacity	↓ number of tumors	152	2
Food extract: American	CRC associated	A/J male treated with	Improving dysbiosis	NR	↓ number of tumors and	153	2

Ginseng	with colitis	AOM and DSS and HFD			histological malignancy		
Food extract and prebiotic: Green tea extract (EGCG) and resistant starch	CRC associated with colitis	Male <i>Sprague-Dawley</i> rats treated with AOM and DSS	↑ <i>Parabacteroides</i> , <i>Barnesiella</i> , <i>Ruminococcus</i> , <i>Marvinbryantia</i> and <i>Bifidobacterium</i> . ↑ acetate, butyrate and propionate.	↑ GPR43. ↓ COX-2, NF-κB, TNF-α and IL-1β.	Resistant starch = ↓ number of tumors and adenocarcinoma formation	154	2
Food extract: American Ginseng	Prevention of colon cancer of genetic origin with a Western diet	Male <i>ApcMin</i> +/- mice on high-fat diet	NR	↓ IL-1α, IL-1β, IL6, TNF-α, G-CSF and GM-CSF	↓ tumor volume and number of tumors	155	2
Clinical studies							
Probiotics							
Probiotic: <i>Bifidobacterium longum</i> , <i>Lactobacillus acidophilus</i> and <i>Enterococcus faecalis</i>	Patients with CRC who have previously undergone radical surgery and who are about to undergo further surgery.	Randomized clinical trial Peri-surgery placebo (n=11), probiotic (n=11). Healthy control patients (n=11).	↑ <i>Enterococcus</i> and ↓ <i>Peptostreptococcus</i> , <i>Comamonas</i> , <i>Fusobacterium</i>	NR	NR	156	2
Probiotic: <i>Bifidobacterium longum</i> , <i>Lactobacillus acidophilus</i> and <i>Enterococcus faecalis</i>	CRC patients whose tumor could be removed by surgery and who are scheduled for surgery	Randomized clinical study Placebo (n=30), preoperative probiotic (n=30)	↑ preoperative percentage <i>Bifidobacterium/E. coli</i>	↑ IgG and sIgA in serum. ↓ endotoxins, D-lactic acid, IL-6 and CRP	↓ incidence of post-surgery infections	157	2
Probiotic: <i>Enterococcus faecalis</i> T110, <i>Clostridium butyricum</i> TO-A and <i>Bacillus mesentericus</i>	CRC patients whose tumor could be removed by surgery and who are scheduled for surgery	Clinical study Control (n=81), Probiotic (n=75)	NR	↓ incisional infections and reduced acute inflammation after surgery	NR	158	2
Probiotic: <i>Lactobacillus plantarum</i> , <i>Lactobacillus acidophilus</i> and <i>Bifidobacterium longum</i>	CRC patients whose tumor could be removed by surgery and who are scheduled for surgery	Randomized double-blind clinical study. Placebo (n=50), perioperative probiotic (n=50).	↑ diversity. ↑ <i>Bifidobacterium</i> and <i>Lactobacilli</i> . ↓ <i>Enterobacteriaceae</i> , <i>Pseudomonas</i> and <i>Candida</i>	↑ claudin1, JAM1 and occludin	NR	159	2
Probiotic: <i>Bifidobacterium longum</i> (BB536) and <i>Lactobacillus johnsonii</i> (La1)	CRC patients whose tumor could be removed	Randomized double-blind clinical study. Placebo (n=10), probiotic	<i>La1</i> = ↑ <i>La1</i> in mucosa and feces. ↓ <i>Enterobacteriaceae</i>	↑ CD3, CD4, CD8 and naive and memory lymphocytes. ↓ CD83-123 markers,	NR	160	2

	by surgery and who are scheduled for surgery	mixture at a dose of ¹⁰⁷ (n=11) and probiotic mixture at a dose of 10 ⁹ (n=11). Peri-surgery treatment		CD83-HLADR, and CD83-11c			
Probiotic: <i>Lactobacillus acidophilus</i> , <i>Lactobacillus casei</i> , <i>Lactobacillus plantarum</i> , <i>Lactobacillus rhamnosus</i> , <i>Bifidobacterium lactis</i> , <i>Bifidobacterium bifidum</i> , <i>Bifidobacterium breve</i> , <i>Streptococcus thermophilus</i>	Stage III colorectal adenocarcinoma	Randomized clinical study of 78 patients with colorectal carcinoma with surgery	NR	NR	↓ number of complications associated with surgery	74	1
Prebiotics							
Prebiotic: food extract: evodiamine	CRC patients	CRC patients undergoing colonoscopies vs. healthy patients without any colorectal disease	↑ <i>E. faecalis</i> and <i>E. coli</i> ↓ <i>Campylobacter</i> , <i>Bifidobacterium</i> and <i>Lactobacillus</i> in CRC. ↑ Endotoxin and D-lactic acid in CRC.	↑ pSTAT3 in cancerous vs. peritumor biopsies	↓ proliferation, p-STAT3 and p-P65 after incubation with evodiamine in colon cancer cell lines HCT-116 and SW-480	133	3
Prebiotic: Rice bran	Patients at high risk of developing CRC	Randomized, double-blind, placebo-controlled trial (placebo = 19, treatment = 20). Placebo = rice powder, rice bran treatment. 30 g every 24h, for 24 weeks.	↑ <i>Firmicutes</i> and <i>Lactobacillus</i>	NR	NR	161	3
Prebiotic: fructooligosaccharides, xylooligosaccharides, polydextrose, and resistant dextrin	CRC patients requiring radical surgery (peri-surgery: pre- and post-surgery are analyzed).	Randomized double-blind clinical study with 140 CRC patients (control = 70; prebiotics = 70)	Pre-surgery = ↑ <i>Bifidobacterium</i> and <i>Enterococcus</i> , ↓ <i>Bacteroides</i> . Post-surgery = ↑ <i>Bifidobacterium</i> and <i>Escherichia-Shigella</i> , ↓ <i>Enterococcus</i>	Pre-surgery = ↑ IgG, IgM and transferrin. Post-surgery = ↑ IgG, TCD3+CD8+ (cytotoxic/suppressive T lymphocytes) and CD19+ (B lymphocytes).	NR	162	2
Symbiotics							
Symbiotic: Maltodextrin as placebo	CRC patients to be treated	Prospective, double-blind, randomized,	NR	↓ plasma IL6 and CRP levels. ↓ post-	3 deaths in the control group and	163	2

and treatment with Simbioflora® (6g fructooligosaccharide, plus <i>Lactobacillus acidophilus</i> NCFM, <i>Lactobacillus rhamnosus</i> HN001, <i>Lactobacillus casei</i> LPC-37 and <i>Bifidobacterium lactis</i> HN019).	with surgery. Stages I-III	placebo-controlled clinical study (placebo; n = 36. Treatment; n = 37).		surgery infections, antibiotic use and hospital stay.	none in the treatment group.		
Symbiotic: <i>Bifidobacterium lactis</i> BI-04, <i>Lactobacillus acidophilus</i> NCFM and inulin	Stage I-III CRCs undergoing surgery	Clinical trial 21 healthy controls (colonoscopy), 15 CRC patients (8 non-intervention, 7 probiotic)	↑ <i>Firmicutes</i> , <i>Clostridiales</i> spp and <i>Faecalibacterium</i>	NR	NR	¹⁶⁴	1
Pre-, pro- and symbiotic							
Prebiotic (resistant starch) probiotic (<i>Bifidobacterium lactis</i>) or combination of both (symbiotic)	Study in healthy subjects for CRC prevention	Randomized double-blind clinical study with crossover treatments. Healthy subjects, n = 17, for 16 weeks, 4 weeks per arm (placebo, prebiotic, probiotic and symbiotic).	Symbiotic = ↑ <i>Lachnospiraceae</i> spp.	No changes in fecal ammonium, SCFA or circulating cytokines. No epithelial changes.	NR	¹⁶⁵	3
Food							
Food extract: Rice bran	CRC patients who have undergone surgery.	Randomized clinical study (control; n = 10. 30g/day rice bran; n = 9)	NR	↑ carbohydrate, lipid, amino acid, cofactor and vitamin metabolism	NR	¹⁶⁶	2
Food extract: Pomegranate extract with high ellagitannin content	CRC patients whose tumor could be removed by surgery	Randomized clinical study. Control (n=10), PE (n=35)	NR	↓ CD44 and CTNNB1 in adjacent healthy tissue and tumor. ↓ CDKN1A, EGFR and TYMS in tumor.	NR	¹⁶⁷	2
Food extract: Pomegranate extract with high ellagitannin content	CRC patients whose tumor could be removed by surgery and who are scheduled for surgery	Randomized double-blind clinical study Control (n=11), pomegranate extract #1 (n=19) and #2 (n=16)	NR	Modulation of miRNAs	NR	¹⁶⁸	2

Increase/activation has been indicated as (↑) and reduction/inhibition as (↓). NR - Not reported. Ref = References

1168



